STOCK TITAN
  1. Home
  2. SEC Filings
  3. CNO
  4. [8-K] CNO Financial Group, Inc. Reports Material Event

CNO Financial lifts 2026 operating EPS midpoint 9%

CNO raised the midpoint of its 2026 operating EPS guidance by 9% and reported a $44.9 million favorable actuarial-review impact.

Filing Impact
(High)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
8-K

Rhea-AI Filing Summary

CNO Financial Group, Inc. reported third-quarter 2026 net income of $161.1 million ($1.71 per diluted share) and net operating income of $179.1 million ($1.90 per diluted share), versus $23.1 million and $127.2 million, respectively, in 3Q25. Operating EPS increased 47%. The comprehensive annual actuarial review had a $44.9 million net favorable impact on both net income and net operating income.

CNO raised 2026 operating EPS guidance, with the midpoint up 9% from prior guidance. Total revenue was $1,086.0 million, compared with $1,188.7 million in 3Q25. During 3Q26, CNO repurchased $60.0 million of common stock, buying 1.1 million shares at an average cost of $54.52 per share. On October 1, 2026, it closed a third reinsurance transaction with its wholly owned Bermuda affiliate, reinsuring approximately $270 million of inforce graded benefit life statutory reserves from Colonial Penn. Total new annualized premiums were up for a 17th consecutive quarter.

2 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major point. Forward-looking: it has not happened yet and may not happen.2026 operating EPS guidance midpoint rose 9% from prior guidance.
  • Moderate pointOperating earnings grew: net operating income +41%; operating EPS +47%.

Negative

  • Moderate pointTotal revenue declined to $1,086.0 million from $1,188.7 million in 3Q25.

Filing Explained

As of September 30, 2026, $240.4 million of repurchase authority remained; holding-company unrestricted cash and investments were $230.7 million.

This 8-K furnishes CNO’s third-quarter results and reports $240.4 million of remaining stock-repurchase authority at September 30, 2026; that is capacity, not an additional buyback already completed or committed.

Unrestricted cash and investments held by the parent company were $230.7 million at September 30, 2026, compared with $351.4 million at December 31, 2025.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Net income $161.1 million Third quarter 2026; $23.1 million in third quarter 2025
Net operating income $179.1 million Third quarter 2026; $127.2 million in third quarter 2025; non-GAAP measure
Net operating income per diluted share $1.90 Third quarter 2026; up 47% from $1.29 in third quarter 2025
Total revenue $1,086.0 million Third quarter 2026; $1,188.7 million in third quarter 2025
2026 operating EPS guidance midpoint Up 9% Raised from prior guidance
Actuarial-review impact $44.9 million net favorable Third quarter 2026 impact on net income and net operating income
Common stock repurchases $60.0 million Third quarter 2026
Statutory risk-based capital ratio 374% Estimated for U.S.-based insurance subsidiaries as of September 30, 2026
Net operating income financial
"Net operating income, a non-GAAP financial measure"
Net operating income is the profit a business makes from its core operations after subtracting the costs directly related to running those operations, but before accounting for taxes, interest, or other expenses. It shows how efficiently a company is generating income from its main activities. Investors use this figure to assess the company's operational performance and profitability.
comprehensive annual actuarial review financial
"impact arising from our comprehensive annual actuarial review"
statutory risk-based capital ratio financial
"consolidated statutory risk-based capital ratio of our U.S. based insurance subsidiaries"
A statutory risk-based capital ratio is a regulator-calculated measure showing how much financial cushion an insurer has relative to the risks it takes, using rules set by insurance authorities rather than general accounting. Investors care because it signals whether a company has enough reserves to withstand losses, similar to a car’s safety rating telling you how well it protects passengers; a low ratio raises the chance of regulatory intervention or reduced dividends.
Funding agreement-backed notes financial
"funding agreement-backed notes ("FABN") program"
Funding agreement-backed notes are bonds whose promised payments come from contracts called funding agreements—guarantees issued by financial or insurance firms to make scheduled payments. For investors, they behave like loans that rely on the creditworthiness of those guarantors rather than a pool of physical assets, so returns can be steady but carry the risk that the contract issuers might fail to pay; understanding the guarantors’ strength and contract terms is key.
accumulated other comprehensive loss financial
"excluding accumulated other comprehensive loss"
Accumulated other comprehensive loss is the running negative total of certain gains and losses that companies record outside their regular profit-and-loss statement, such as changes in the value of some investments, pension adjustments, or currency translation effects. It matters to investors because it reduces shareholders’ equity and reveals economic swings that haven’t affected reported net income yet — like a side ledger showing pending ups and downs that could influence future cash flow or balance-sheet strength.
Net income $161.1 million versus $23.1 million in third quarter 2025
Net operating income $179.1 million up 41% from $127.2 million in third quarter 2025
Operating EPS $1.90 per diluted share up 47% from $1.29 in third quarter 2025
Total revenue $1,086.0 million versus $1,188.7 million in third quarter 2025
Guidance

CNO raised 2026 operating EPS guidance, with the midpoint up 9% from prior guidance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did CNO earn in Q3 2026?
CNO reported net income of $161.1 million ($1.71 per diluted share) and net operating income of $179.1 million ($1.90 per diluted share) in 3Q26. The comprehensive annual actuarial review had a $44.9 million net favorable impact on both measures.

What changed in CNO's 2026 operating EPS guidance?
CNO raised its full-year 2026 operating EPS guidance, with the midpoint up 9% from prior guidance.

What was CNO's statutory risk-based capital ratio?
The consolidated statutory risk-based capital ratio of CNO's U.S.-based insurance subsidiaries was estimated at 374% as of September 30, 2026. The estimate reflected third-quarter statutory operating gain of $21.9 million.

How much did CNO pay in common dividends in Q3 2026?
CNO paid $16.5 million in dividends on common stock during 3Q26.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Available on EDGAR Accepted by SEC EDGAR
0001224608falsetrue00012246082026-10-292026-10-290001224608us-gaap:CommonStockMember2026-10-292026-10-290001224608cno:RightsToPurchaseSeriesFJuniorParticipatingPreferredStockMember2026-10-292026-10-290001224608cno:A5125SubordinatedDebenturesDue2060Member2026-10-292026-10-29


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 29, 2026

CNO Financial Group, Inc.
(Exact Name of Registrant as Specified in Charter)
 
Delaware001-3179275-3108137
(State or Other
Jurisdiction of Incorporation)		(Commission File Number)(I.R.S. Employer
Identification No.)
11299 Illinois Street
Carmel, Indiana  46032
(Address of Principal Executive Offices) (Zip Code)

(317) 817-6100
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, par value $0.01 per shareCNONew York Stock Exchange
Rights to purchase Series F Junior Participating Preferred StockNew York Stock Exchange
5.125% Subordinated Debentures due 2060CNOpANew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02.Results of Operations and Financial Condition.

On October 29, 2026, CNO Financial Group, Inc. ("CNO" or the "Company") issued: (i) a press release announcing its financial results for the quarter ended September 30, 2026, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference; (ii) the Quarterly Financial Supplement for September 30, 2026, a copy of which is attached hereto as Exhibit 99.2 and is incorporated herein by reference; and (iii) additional financial information related to its financial and operating results for the quarter ended September 30, 2026, a copy of which is attached hereto as Exhibit 99.3 and is incorporated herein by reference.

The information contained under Item 2.02 in this Current Report on Form 8-K (including Exhibits 99.1, 99.2 and 99.3) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information contained in this Current Report on Form 8-K shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.


Item 9.01(d).Financial Statements and Exhibits.

The following materials are furnished as exhibits to this Current Report on Form 8-K:

99.1
Press release dated October 29, 2026 related to financial results for the quarter ended September 30, 2026.
99.2
Quarterly Financial Supplement - 3Q2026.
99.3
Third Quarter 2026 Financial and Operating Results for the period ended September 30, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).





2



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CNO Financial Group, Inc.
Date: October 29, 2026
By:
/s/ Joel T. Koehneman
Joel T. Koehneman
Senior Vice President and
Chief Accounting Officer




3


cnologopr.jpg                            News

For Immediate Release


CNO Financial Group Reports Third Quarter 2026 Results

Carmel, Ind., October 29, 2026 - CNO Financial Group, Inc. (NYSE: CNO) today reported its third quarter 2026 financial results:
•Raising 2026 operating earnings per share (EPS) guidance with the midpoint up 9% from our prior guidance.
•Net income was $161 million, or $1.71 per diluted share, and net operating income(1) was $179 million, or $1.90 per diluted share. Significant items related to the comprehensive annual actuarial review had a $44.9 million net favorable impact on both net income and net operating income.
•Operating EPS grew 47% in the quarter and 43% year-to-date.
•Return on equity (ROE) of 16.4%; Operating ROE(5) of 14.1%, excluding significant items(5).
•Book value per share of $25.34; Book value per diluted share, excluding accumulated other comprehensive loss,(2) of $41.29, up 8%.
•Total new annualized premiums (NAP)(4) up for a 17th consecutive quarter; Continued growth in asset accumulation products.
•Consumer and Worksite delivered their 15th and 17th consecutive quarters of producing agent count growth, respectively.
•On October 1, 2026, closed a 3rd reinsurance transaction with CNO’s wholly owned Bermuda affiliate, reinsuring approximately $270 million of inforce graded benefit life statutory reserves from Colonial Penn.

“CNO delivered an excellent quarter, with operating earnings per share up 47% and our 17th consecutive quarter of sales growth,” said Gary C. Bhojwani, chief executive officer.

“Our momentum reflects disciplined execution across the business and continued improvement in profitability. Based on these results, we are raising our full-year operating earnings per share guidance. We also executed our 3rd reinsurance transaction with our Bermuda affiliate, supporting our focus on serving middle-income households. We remain committed to driving sustained, profitable growth and creating long-term value for our shareholders.”





FINANCIAL SUMMARY
Quarter End
(Amounts in millions, except per share data)
(Unaudited)

Net operating income, a non-GAAP(a) financial measure, is used consistently by CNO’s management to evaluate the operating performance of the Company and is a measure commonly used in the life insurance industry. It differs from net income primarily because it excludes the non-operating items as defined in note (1), which are primarily non-economic accounting impacts and other non-operating items. Management believes an analysis of net operating income is important in understanding the profitability and operating trends of the Company’s business. Net income is the most directly comparable GAAP measure.

Significant items positively impacted both net income and net operating income(1) by $44.9 million, or $0.48 per diluted share, in 3Q26 compared to $32.2 million, or $0.33 per diluted share, in 3Q25. Significant items are detailed in note (6).
Per diluted share
Quarter endedQuarter ended
September 30,September 30,
20262025% change20262025% change
Income from insurance products (b)
$1.83 $1.52 20 %$172.0 $149.5 15 %
Fee income(0.01)(0.04)(75)(1.1)(3.9)(72)
Investment income not allocated to product lines (c)
0.72 0.40 80 68.1 39.5 72 
Expenses not allocated to product lines(0.20)(0.23)(13)(18.8)(22.3)(16)
Operating earnings before taxes2.34 1.65 220.2 162.8 
Income tax expense on operating income(0.44)(0.36)22 (41.1)(35.6)15 
Net operating income (1)1.90 1.29 47 179.1 127.2 41 
Net realized investment losses from disposals, impairments and change in allowance for credit losses
(0.51)(0.09)(48.3)(8.8)
Net change in market value of investments recognized in earnings(0.17)0.06 (16.4)5.8 
Changes in fair value of embedded derivative liabilities and market risk benefits0.74 (0.18)69.7 (18.1)
Expenses related to TechMod initiative
(0.11)(0.07)(10.1)(7.2)
Goodwill and other asset impairment
— (0.98)— (96.7)
Other0.11 (0.02)11.3 (1.6)
Non-operating income before taxes
0.06 (1.28)6.2 (126.6)
Income tax expense:
On non-operating income(0.02)0.23 (2.1)22.5 
Valuation allowance for deferred tax assets(0.23)— (22.1)— 
     Net non-operating income (0.19)(1.05)(18.0)(104.1)
Net income$1.71 $0.24 $161.1 $23.1 
Weighted average diluted shares outstanding94.3 98.6 
____________________
(a)    GAAP is defined as accounting principles generally accepted in the United States of America.
(b)    Income from insurance products is the sum of the insurance product margins of the annuity, health and life product lines, less expenses allocated to the insurance product lines. It excludes the income from our fee income business, investment income not allocated to product lines, net expenses not allocated to product lines (primarily holding company expenses) and income taxes. Insurance product margin is management’s measure of the profitability of its annuity, health and life product lines’ performance and consists of insurance policy income plus allocated investment income less insurance policy benefits, interest credited, commissions, advertising expense and amortization of acquisition costs.
(c)    Investment income not allocated to product lines represents net investment income less: (i) equity returns credited to policyholder account balances; (ii) the investment income allocated to our product lines; (iii) interest expense on notes payable, investment borrowings and financing arrangements; (iv) expenses related to the funding agreement-backed notes ("FABN") program; and (v) certain expenses related to benefit plans that are offset by special-purpose investment income; plus (vi) the impact of annual option forfeitures related to fixed indexed annuity surrenders. Investment income not allocated to product lines includes investment income on investments in excess of amounts allocated to product lines, investments held by our holding companies, the spread we earn from our Federal Home Loan Bank ("FHLB") investment borrowing and FABN programs and variable components of investment income (including call and prepayment income, adjustments to returns on structured securities due to cash flow changes, income (loss) from company-owned life insurance ("COLI") and alternative investment income not allocated to product lines), net of interest expense on corporate debt and financing arrangements. The spread earned from our FHLB investment borrowing and FABN programs includes the investment income on the matched assets less: (i) interest on investment borrowings related to the FHLB investment borrowing program; (ii) interest credited on funding agreements; and (iii) amortization of deferred acquisition costs related to the FABN program.
2

FINANCIAL SUMMARY (continued)
Management vs. GAAP Measures
(Dollars in millions, except per share data)
(Unaudited)

Shareholders’ equity, excluding accumulated other comprehensive income (loss), and book value per share, excluding accumulated other comprehensive income (loss), are non-GAAP measures that are utilized by management to view the business without the effect of accumulated other comprehensive income (loss) which is primarily attributable to fluctuations in interest rates associated with fixed maturities, available for sale. Management views the business in this manner because the Company has the ability and generally, the intent, to hold investments to maturity and meaningful trends can be more easily identified without the fluctuations. In addition, shareholders' equity excludes net operating loss carryforwards in our non-GAAP return on equity measures as such assets are not discounted and, accordingly, will not provide a return to shareholders until after it is realized as a reduction to taxes that would otherwise be paid. Management believes that excluding this value from the equity component of this measure enhances the understanding of the effect these non-discounted assets have on operating returns.
___________________________________________________________________________________________________

Quarter ended
September 30,
20262025
Trailing four quarters:
Net Income$417.6 $319.3 
Net operating income (a non-GAAP financial measure)543.3 433.8 
Net operating income, excluding significant items (a non-GAAP financial measure)498.4 399.4 
Average of each of the trailing four quarters average:
Shareholders’ equity$2,548.9 $2,560.6 
Accumulated other comprehensive loss1,211.9 1,245.2 
Shareholders’ equity, excluding accumulated other comprehensive loss3,760.8 3,805.8 
Net operating loss carryforwards(238.1)(225.8)
Shareholders' equity, excluding accumulated other comprehensive loss and net operating loss carryforwards$3,522.7 $3,580.0 
Ratios:
Return on equity 16.4 %12.5 %
Operating return on equity (a non-GAAP financial measure) (5)
15.4 %12.1 %
Operating return on equity, excluding significant items (a non-GAAP financial measure) (5)
14.1 %11.2 %

Shareholders’ equity$2,323.7 $2,611.0 
Accumulated other comprehensive loss1,545.8 1,118.9 
Shareholders’ equity, excluding accumulated other comprehensive loss$3,869.5 $3,729.9 
Basic shares outstanding91,705,50995,840,989
Diluted shares outstanding93,720,62697,902,763
Book value per share$25.34 $27.24 
Book value per diluted share$24.79 $26.67 
Accumulated other comprehensive loss per diluted share
16.50 11.43 
Book value per diluted share, excluding accumulated other comprehensive loss (a non-GAAP financial measure) (2)
$41.29 $38.10 

3

Non-Operating Items
Net realized investment losses in 3Q26 were $48.3 million, including the unfavorable change in the allowance for credit losses of $5.4 million. Net realized investment losses in 3Q25 were $8.8 million, including the favorable change in the allowance for credit losses of $8.0 million.

During 3Q26 and 3Q25, we recognized a decrease in earnings of $16.4 million and an increase of $5.8 million, respectively, due to the net change in market value of investments.

During 3Q26 and 3Q25, we recognized an increase in earnings of $69.7 million and a decrease of $18.1 million, respectively, resulting from changes in the estimated fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities. Such amounts include the impacts of changes in market interest rates and equity impacts used to determine the estimated fair values of the embedded derivatives and market risk benefits and the unfavorable impact resulting from our comprehensive annual actuarial review of $11.2 million and $14.3 million in 3Q26 and 3Q25, respectively.

During 3Q26 and 3Q25, we incurred $10.1 million and $7.2 million, respectively, of expense related to TechMod, our technology modernization initiative that began in 2025.

During 3Q26, other non-operating items primarily included a $10.0 million mark-to-market change in the agent deferred compensation plan liability, which was impacted by changes in the underlying actuarial assumptions used to value the liability. We recognize the mark-to-market change in the estimated value of this liability through earnings as assumptions change.

During 3Q25, we recognized a $96.7 million non-operating charge for the impairment of goodwill and other assets related to the acquisitions of Web Benefits Design and DirectPath in 2019 and 2021, respectively. This reflected macroeconomic uncertainty and market conditions including the decline in the value of comparable publicly traded companies and revised financial projections for the business.

During 3Q26, we recognized a $22.1 million valuation allowance on deferred tax assets associated with capital loss carryforwards. The valuation allowance reflects realized capital losses generated primarily from asset sales in anticipation of executing the internal reinsurance transaction on October 1, 2026, portfolio optimization activities, and from capital loss allocations from partnership investments together with a reduction in unrealized capital gains available to support realization of those losses as interest rates increased.


Statutory (based on non-GAAP measures) and GAAP Capital Information
The consolidated statutory risk-based capital ratio of our U.S. based insurance subsidiaries was estimated at 374% at September 30, 2026, reflecting estimated 3Q26 statutory operating gain of $21.9 million. There were no company dividends paid to the holding company during 3Q26.

During 3Q26, we repurchased $60.0 million of common stock under our securities repurchase program. We repurchased 1.1 million common shares at an average cost of $54.52 per share. As of September 30, 2026, we had 91.7 million shares outstanding and had authority to repurchase up to an additional $240.4 million of our common stock. During 3Q26, dividends paid on common stock totaled $16.5 million.

Unrestricted cash and investments held by our holding company were $230.7 million at September 30, 2026 compared to $351.4 million at December 31, 2025.

Book value per common share was $25.34 at September 30, 2026 compared to $27.92 at December 31, 2025. Book value per diluted share, excluding accumulated other comprehensive income (loss) (2), was $41.29 at September 30, 2026 compared to $38.81 at December 31, 2025.

The debt-to-capital ratio was 36.5% and 33.6% at September 30, 2026 and December 31, 2025, respectively. Our debt-to-total capital ratio, excluding accumulated other comprehensive income (loss)(3), was 25.7% and 26.2% at September 30, 2026 and December 31, 2025, respectively.

Return on equity for the trailing four quarters ended September 30, 2026 and 2025 was 16.4% and 12.5%, respectively. Operating return on equity, excluding significant items(5), for the trailing four quarters ended September 30, 2026 and 2025 was 14.1% and 11.2%, respectively.

In this news release, CNO includes non-GAAP measures to enhance investors’ understanding of management’s view of the business. The non-GAAP measures are not a substitute for GAAP, but rather a supplement to increase transparency by providing a broader perspective. CNO’s definitions of non-GAAP measures may differ from other companies’ definitions. More detailed information including various GAAP and non-GAAP measurements are located at CNOinc.com in the Investors section under SEC Filings.


4

CAUTION REGARDING FORWARD-LOOKING STATEMENTS:

This press release may contain forward-looking statements within the meaning of federal securities laws. These prospective statements reflect management’s current expectations, but are not guarantees of future performance. Accordingly, please refer to CNO’s cautionary statement regarding forward-looking statements, and the business environment in which the Company operates, contained in the Company’s Form 10-K for the year ended December 31, 2025 and any subsequent Form 10-Q or Form 10-K on file with the Securities and Exchange Commission and on the Company’s website at CNOinc.com in the Investors section.  CNO specifically disclaims any obligation to update or revise any forward-looking statement because of new information, future developments or otherwise.


EARNINGS RELEASE CONFERENCE CALL WEBCAST:

The Company will host a conference call to discuss results on October 30, 2026 at 11:00 a.m. Eastern Time. During the call, we will be referring to a presentation that will be available at the Investors section of the company's website.

To participate by dial-in, please register at https://register-conf.media-server.com/register/BI92346cd8ec894d29bcfdf06f719c8513. Upon registering, you will be provided with call details and a unique PIN to join the call as well as an email confirmation with details.

For those investors who prefer to listen to the call online, we will be broadcasting the call live via webcast. The event can be accessed through the Investors section of the company's website: ir.CNOinc.com. Participants should go to the website at least 15 minutes before the event to register and download any necessary audio software.


ABOUT CNO FINANCIAL GROUP

CNO Financial Group, Inc. (NYSE: CNO) secures the future of middle-income America. CNO provides life and health insurance, annuities and financial services through our family of brands, including Bankers Life, Colonial Penn, Optavise and Washington National. Our customers work hard to save for the future, and we help protect their health, income and retirement needs with 3.3 million policies and $39.3 billion in total assets. Our 3,200 associates, 5,100 exclusive agents and more than 6,500 independent partner agents guide individuals, families and businesses through a lifetime of financial decisions. For more information, visit CNOinc.com.
5


CNO FINANCIAL GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF OPERATIONS
(Dollars in millions, except per share data)
(unaudited)
Three months endedNine months ended
September 30,September 30,
2026202520262025
Revenues:
Insurance policy income$688.2 $658.4 $2,042.3 $1,960.4 
Net investment income:
General account assets441.5 382.9 1,248.4 1,136.3 
Policyholder and other special-purpose portfolios6.1 116.8 126.3 158.6 
Investment gains (losses):
Realized investment losses(32.6)(12.9)(49.0)(38.0)
Other investment (losses) gains(32.1)9.9 (53.1)9.8 
Total investment losses
(64.7)(3.0)(102.1)(28.2)
Fee revenue and other income14.9 33.6 85.9 117.2 
Total revenues1,086.0 1,188.7 3,400.8 3,344.3 
Benefits and expenses:
Insurance policy benefits565.1 702.1 1,884.2 1,930.5 
Liability for future policy benefits remeasurement gain
(52.5)(30.8)(74.3)(55.8)
Change in fair value of market risk benefits(28.8)(12.4)(26.4)(8.0)
Interest expense58.1 56.6 164.3 177.7 
Amortization of deferred acquisition costs and present value of future profits 76.8 69.9 225.9 205.9 
Goodwill and other asset impairment
— 96.7 — 96.7 
Gain on extinguishment of borrowings related to variable interest entities
— — — (1.5)
Other operating costs and expenses240.9 270.4 792.6 816.8 
Total benefits and expenses859.6 1,152.5 2,966.3 3,162.3 
Income before income taxes226.4 36.2 434.5 182.0 
Income tax expense65.3 13.1 109.8 45.6 
Net income$161.1 $23.1 $324.7 $136.4 
Earnings per common share:
Basic:
Weighted average shares outstanding92,195,000 96,603,000 93,156,000 98,639,000 
Net income$1.75 $0.24 $3.49 $1.38 
Diluted:
Weighted average shares outstanding94,253,000 98,553,000 95,115,000 100,670,000 
Net income$1.71 $0.24 $3.41 $1.36 

NOTES
(1)Management believes that an analysis of net income applicable to common stock before the following items (each net of tax, except as noted) is important to evaluate the financial performance of the Company, and is a key measure commonly used in the life insurance industry: (i) net realized investment gains or losses from disposals, impairments and the change in allowance for credit losses; (ii) net change in market value of investments recognized in earnings; (iii) changes in fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities; (iv) fair value changes related to the agent deferred compensation plan; (v) gains or losses related to material reinsurance transactions; (vi) loss on extinguishment of debt; (vii) changes in the valuation allowance for deferred tax assets and other tax items; (viii) costs related to our three-year project to modernize certain elements of our technology ("TechMod") that are incremental to normal spend and will not recur following implementation; (ix) goodwill and other asset impairment expenses; (x) gains or losses related to divested business; and (xi) other non-operating items including earnings attributable to variable interest entities (collectively, "net operating income," a non-GAAP financial measure). The income tax expense or benefit allocated to the items included in net non-operating income (loss) represents the current and deferred income tax expense or benefit allocated to the items included in non-operating earnings. Management believes this information provides a better understanding of the business and a more meaningful analysis of results of our insurance product lines. A reconciliation of net operating income to net income applicable to common stock is provided in the table on page 2. Additional information
6

concerning this non-GAAP measure is included in our periodic filings with the Securities and Exchange Commission that are available on CNO's website, CNOinc.com, in the Investors section under SEC Filings.
(2)Book value per diluted share reflects the potential dilution that could occur if outstanding stock options were exercised and restricted stock and performance units were vested. The dilution from options, restricted shares and performance units is calculated using the treasury stock method. Under this method, we assume the proceeds from the exercise of the options (or the unrecognized compensation expense with respect to restricted stock and performance units) will be used to purchase shares of our common stock at the closing market price on the last day of the period. In addition, the calculation of this non-GAAP measure differs from the corresponding GAAP measure because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure. Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in the unrealized appreciation (depreciation) of our investments.
(3)The calculation of this non-GAAP measure differs from the corresponding GAAP measure because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure. Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in the unrealized appreciation (depreciation) of our investments.
(4)Measured by new annualized premiums for life and health products, which includes 10% of single premium whole life deposits and 100% of all other premiums (excluding annuities). Sales of third-party products are excluded.
(5)Operating return on equity and operating return on equity, excluding significant items are calculated as follows: (i) operating return on equity is equal to the trailing four quarters of net operating income(1) divided by average shareholders' equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards; and (ii) operating return on equity, excluding significant items is equal to the trailing four quarters of net operating income(1), excluding significant items, divided by average shareholders' equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards, for the trailing four quarters. Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in accumulated other comprehensive loss. Such volatility is often caused by changes in the estimated fair value of our investment portfolio resulting from changes in general market interest rates rather than the business decisions made by management. In addition, our equity includes the value of significant net operating loss carryforwards (included in income tax assets on our consolidated balance sheet). In accordance with GAAP, these assets are not discounted, and accordingly will not provide a return to shareholders until after they are realized as a reduction to taxes that would otherwise be paid. Management believes that excluding this value from the equity component of this measure enhances the understanding of the effect these non-discounted assets have on operating returns and the comparability of these measures from period to period. However, this non-GAAP measure does not replace the corresponding GAAP measure.



7

The following summarizes: (i) net operating income; (ii) significant items; (iii) net operating income, excluding significant items; and (iv) net income (loss) (dollars in millions):
Net operating
Net operatingincome,
income,excludingNet
excludingsignificantincome -
Net operatingSignificantsignificantitems - trailingNettrailing
incomeitemsitems (a)four quartersincome (loss)four quarters
4Q24$138.0 $3.1 
(b)
$141.1 $410.5 $182.9 $420.8 
1Q2581.1 (5.3)
(c)
75.8 428.8 21.5 330.0 
2Q2587.5 — 87.5 401.7 91.8 305.5 
3Q25127.2 (32.2)(d)95.0 399.4 23.1 319.3 
4Q25143.4 — 143.4 401.7 92.9 229.3 
1Q26101.3 — 101.3 427.2 37.7 245.5 
2Q26119.5 — 119.5 459.2 125.9 279.6 
3Q26179.1 (44.9)(e)134.2 498.4 161.1 417.6 
(a) See note (6) for additional information.
(b) Comprised of $3.9 million of the unfavorable impact arising from our comprehensive annual actuarial review, net of tax expense of $0.8 million.
(c) Comprised of $6.8 million of the favorable impact of an out-of-period adjustment which decreased reserves, net of tax expense of $1.5 million.
(d) Comprised of $41.3 million of the net favorable impact arising from our comprehensive annual actuarial review, net of tax expense of $9.1 million.
(e) Comprised of $56.3 million of the net favorable impact arising from our comprehensive annual actuarial review, net of tax expense of $11.4 million.

A reconciliation of pre-tax operating earnings (a non-GAAP financial measure) to net income is as follows (dollars in millions):
Trailing four quarters
3Q263Q25
Pre-tax operating earnings (a non-GAAP financial measure)$674.6 $553.6 
Income tax expense(131.3)(119.8)
Net operating income543.3 433.8 
Non-operating items:
Net realized investment losses from disposals, impairments and change in allowance for credit losses
(102.3)(78.9)
Net change in market value of investments recognized in earnings(26.3)9.0 
Changes in fair value of embedded derivative liabilities and market risk benefits60.4 30.1 
Fair value changes related to the agent deferred compensation plan8.3 6.6 
Expenses related to TechMod initiative
(43.4)(10.4)
Goodwill and other asset impairment
(5.2)(96.7)
Net loss related to divested business
(20.3)— 
Other0.1 0.8 
Non-operating loss before taxes(128.7)(139.5)
Income tax (expense) benefit:
    Income tax benefit on non-operating loss25.1 25.0 
    Valuation allowance for deferred tax assets(22.1)— 
Net non-operating loss(125.7)(114.5)
Net income$417.6 $319.3 

8

A reconciliation of consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) to common shareholders’ equity, is as follows (dollars in millions):

1Q242Q243Q244Q24
Consolidated capital, excluding accumulated other comprehensive
income (loss) and net operating loss carryforwards
(a non-GAAP financial measure)$3,536.8 $3,596.7 $3,529.9 $3,810.0 
Net operating loss carryforwards311.2 296.5 273.9 76.6 
Accumulated other comprehensive loss(1,480.3)(1,464.3)(1,116.0)(1,371.4)
Common shareholders' equity$2,367.7 $2,428.9 $2,687.8 $2,515.2 
1Q252Q253Q254Q25
Consolidated capital, excluding accumulated other comprehensive
income (loss) and net operating loss carryforwards
(a non-GAAP financial measure)$3,498.9 $3,504.3 $3,483.6 $3,510.2 
Net operating loss carryforwards295.3 271.1 246.3 243.0 
Accumulated other comprehensive loss(1,239.1)(1,252.7)(1,118.9)(1,115.0)
Common shareholders' equity$2,555.1 $2,522.7 $2,611.0 $2,638.2 
1Q262Q263Q26
Consolidated capital, excluding accumulated other comprehensive
income (loss) and net operating loss carryforwards
(a non-GAAP financial measure)$3,461.2 $3,548.5 $3,658.3 
Net operating loss carryforwards254.8 225.9 211.2 
Accumulated other comprehensive loss(1,217.6)(1,182.8)(1,545.8)
Common shareholders' equity$2,498.4 $2,591.6 $2,323.7 

A reconciliation of consolidated capital, excluding accumulated other comprehensive loss and net operating loss carryforwards (a non-GAAP financial measure) to common shareholders’ equity, is as follows (dollars in millions):
Trailing four quarter average
3Q263Q25
Consolidated capital, excluding accumulated other comprehensive
income (loss) and net operating loss carryforwards
(a non-GAAP financial measure)$3,522.7 $3,580.0 
Net operating loss carryforwards238.1 225.8 
Accumulated other comprehensive loss(1,211.9)(1,245.2)
Common shareholders' equity$2,548.9 $2,560.6 



9

(6)    The tables below summarize the financial impact of significant items on our net operating income for the quarters during the nine months ended September 30, 2026 and the year ended December 31, 2025 that had significant items impacting our net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results (dollars in millions, except per share data).

Three months ended
September 30, 2026
Actual resultsSignificant itemsExcluding significant
items
Insurance product margin
Annuity margin$87.9 $(20.5)(a)$67.4 
Health margin149.1 (7.8)(a)141.3 
Life margin96.0 (28.0)(a)68.0 
Total insurance product margin333.0 (56.3)276.7 
Allocated expenses(161.0)— (161.0)
Income from insurance products172.0 (56.3)115.7 
Fee income(1.1)— (1.1)
Investment income not allocated to product lines68.1 — 68.1 
Expenses not allocated to product lines(18.8)— (18.8)
Operating earnings before taxes220.2 (56.3)163.9 
Income tax (expense) benefit on operating income(41.1)11.4 (29.7)
Net operating income $179.1 $(44.9)$134.2 
Net operating income per diluted share$1.90 $(0.48)$1.42 

(a)Comprised of $56.3 million of the net favorable impact arising from our comprehensive annual actuarial review.

Three months ended
September 30, 2025
Actual resultsSignificant itemsExcluding significant
items
Insurance product margin
Annuity margin$72.9 $(16.6)(a)$56.3 
Health margin157.0 (21.1)(a)135.9 
Life margin70.6 (3.6)(a)67.0 
Total insurance product margin300.5 (41.3)259.2 
Allocated expenses(151.0)— (151.0)
Income from insurance products
149.5 (41.3)108.2 
Fee income(3.9)— (3.9)
Investment income not allocated to product lines
39.5 — 39.5 
Expenses not allocated to product lines(22.3)— (22.3)
Operating earnings before taxes162.8 (41.3)121.5 
Income tax (expense) benefit on operating income(35.6)9.1 (26.5)
Net operating income
$127.2 $(32.2)$95.0 
Net operating income per diluted share$1.29 $(0.33)$0.96 
___________
(a)Comprised of $41.3 million of the net favorable impact arising from our comprehensive annual actuarial review.

10

11
Three months ended
March 31, 2025
Actual resultsSignificant itemsExcluding significant
items
Insurance product margin
Annuity margin$54.5 $— $54.5 
Health margin126.2 — 126.2 
Life margin68.2 (6.8)(a)61.4 
Total insurance product margin248.9 (6.8)242.1 
Allocated expenses(161.2)— (161.2)
Income from insurance products
87.7 (6.8)80.9 
Fee income(0.8)— (0.8)
Investment income not allocated to product lines
38.0 — 38.0 
Expenses not allocated to product lines(20.3)— (20.3)
Operating earnings before taxes104.6 (6.8)97.8 
Income tax (expense) benefit on operating income(23.5)1.5 (22.0)
Net operating income
$81.1 $(5.3)$75.8 
Net operating income per diluted share$0.79 $(0.05)$0.74 
___________
(a)Comprised of $6.8 million of the favorable impact of an out-of-period adjustment, which decreased reserves.


For further information:

CNO News Media
Valerie Dolenga
Valerie.Dolenga@CNOinc.com

CNO Investor Relations
Adam Auvil
Adam.Auvil@CNOinc.com







cnologosuppa.jpg


Quarterly Financial Supplement - 3Q2026
October 29, 2026

Page 1


Table of ContentsPage
Consolidated balance sheet3
Consolidated statement of operations4
Financial summary5
Insurance operations6
Margin from insurance products7-9
Collected premiums and insurance policy income10
Health and life new annualized premiums11
Computation of weighted average shares outstanding12
Annuities - account value rollforwards13
Consolidated statutory information of U.S. based insurance subsidiaries14
Investment income not allocated to product lines and investment income allocated to product lines
15-16
Other investment data17
Significant items
17-18
Notes19-20

Page 2


CNO FINANCIAL GROUP, INC.
CONSOLIDATED BALANCE SHEET
(Dollars in millions)
(Unaudited)
Mar-25Jun-25Sep-25Dec-25Mar-26Jun-26Sep-26
Assets
Investments:
  Fixed maturities, available for sale, at fair value$23,283.0 $23,047.0 $23,405.3 $23,886.8 $23,881.1 $24,495.7 $23,677.6 
  Equity securities at fair value
349.1 387.4 377.2 389.2 332.8 337.2 328.0 
  Mortgage loans2,601.2 2,834.3 3,042.7 3,256.8 3,347.8 3,356.3 3,437.1 
  Policy loans136.4 137.6 141.2 140.9 141.8 144.2 145.6 
  Trading securities308.0 308.3 296.9 294.8 280.2 258.6 234.0 
  Investments held by variable interest entities380.2 376.9 296.8 293.0 287.4 292.3 307.8 
  Other invested assets1,386.7 1,500.5 1,617.0 1,737.0 1,695.1 1,858.6 1,912.0 
  Total investments
28,444.6 28,592.0 29,177.1 29,998.5 29,966.2 30,742.9 30,042.1 
Cash and cash equivalents - unrestricted928.2 766.0 1,218.3 956.1 1,129.5 1,289.7 1,409.4 
Cash and cash equivalents held by variable interest entities96.6 50.0 23.3 27.4 24.8 16.3 12.0 
Accrued investment income289.6 279.4 282.0 286.0 284.2 302.5 302.3 
Present value of future profits156.5 152.1 147.8 143.6 139.5 135.5 131.7 
Deferred acquisition costs2,209.9 2,276.3 2,343.7 2,397.3 2,441.3 2,508.1 2,570.3 
Reinsurance receivables3,804.3 3,753.9 3,731.7 3,677.5 3,611.1 3,568.5 3,479.9 
Income tax assets, net
768.0 749.3 708.1 713.3 748.9 709.7 759.8 
Assets held in separate accounts3.1 2.9 2.7 2.8 2.7 3.0 2.9 
Other assets728.4 707.2 661.5 588.1 615.2 585.0 596.3 
Total assets$37,429.2 $37,329.1 $38,296.2 $38,790.6 $38,963.4 $39,861.2 $39,306.7 
Liabilities
Liabilities for insurance products:
  Policyholder account balances$17,314.3 $17,609.0 $18,290.3 $18,912.6 $18,997.3 $19,640.9 $19,819.3 
  Future policy benefits11,773.0 11,787.7 11,975.5 11,898.0 11,722.2 11,784.7 10,988.3 
  Market risk benefit liability73.6 63.8 52.6 48.1 58.1 50.6 21.9 
  Liability for life insurance policy claims63.5 60.7 61.5 58.4 58.8 61.8 63.0 
  Unearned and advanced premiums221.5 217.3 214.5 228.0 225.2 219.0 227.2 
  Liabilities related to separate accounts3.1 2.9 2.7 2.8 2.7 3.0 2.9 
Other liabilities1,027.2 935.8 1,036.9 952.8 1,098.6 957.1 1,047.0 
Investment borrowings2,188.6 2,441.7 2,441.7 2,441.7 2,691.7 2,941.7 3,191.7 
Borrowings related to variable interest entities375.1 352.8 274.3 274.4 274.4 274.5 285.0 
Notes payable - direct corporate obligations1,834.2 1,334.7 1,335.2 1,335.6 1,336.0 1,336.3 1,336.7 
Total liabilities34,874.1 34,806.4 35,685.2 36,152.4 36,465.0 37,269.6 36,983.0 
Shareholders' equity
Common stock1.0 1.0 1.0 0.9 0.9 0.9 0.9 
Additional paid-in capital1,535.0 1,441.4 1,389.4 1,336.3 1,277.8 1,227.4 1,178.3 
Retained earnings
2,258.2 2,333.0 2,339.5 2,416.0 2,437.3 2,546.1 2,690.3 
Total shareholders' equity before accumulated other comprehensive loss3,794.2 3,775.4 3,729.9 3,753.2 3,716.0 3,774.4 3,869.5 
Accumulated other comprehensive loss(1,239.1)(1,252.7)(1,118.9)(1,115.0)(1,217.6)(1,182.8)(1,545.8)
Total shareholders' equity2,555.1 2,522.7 2,611.0 2,638.2 2,498.4 2,591.6 2,323.7 
Total liabilities and shareholders' equity$37,429.2 $37,329.1 $38,296.2 $38,790.6 $38,963.4 $39,861.2 $39,306.7 
Book value per common share$25.58 $25.92 $27.24 $27.92 $26.64 $27.96 $25.34 
Book value per common share, excluding accumulated other comprehensive loss (1) (2)$37.98 $38.79 $38.92 $39.72 $39.62 $40.72 $42.19 
Book value per diluted share, excluding accumulated other comprehensive loss (1) (3)$37.27 $38.05 $38.10 $38.81 $38.98 $39.92 $41.29 

Page 3


CNO FINANCIAL GROUP, INC.
CONSOLIDATED STATEMENT OF OPERATIONS
(Dollars in millions)
(Unaudited)

1Q2Q3Q4QYTD1Q2Q3Q
20252025202520252025202620262026
Revenues
Insurance policy income$650.7 $651.3 $658.4 $662.2 $2,622.6 $673.4 $680.7 $688.2 
Net investment income:
   General account assets375.1 378.3 382.9 406.1 1,542.4 395.0 411.9 441.5 
Policyholder and other special-purpose portfolios(63.6)105.4 116.8 22.4 181.0 (64.9)185.1 6.1 
Investment gains (losses):
Realized investment losses(3.8)(21.3)(12.9)(21.6)(59.6)(7.8)(8.6)(32.6)
Other investment (losses) gains
(3.0)2.9 9.9 (4.9)4.9 (14.9)(6.1)(32.1)
Total investment losses
(6.8)(18.4)(3.0)(26.5)(54.7)(22.7)(14.7)(64.7)
Fee revenue and other income48.7 34.9 33.6 78.9 196.1 48.8 22.2 14.9 
Total revenues1,004.1 1,151.5 1,188.7 1,143.1 4,487.4 1,029.6 1,285.2 1,086.0 
Benefits and expenses
Insurance policy benefits570.0 658.4 702.1 617.7 2,548.2 576.6 742.5 565.1 
Liability for future policy benefits remeasurement gain
(12.2)(12.8)(30.8)(14.9)(70.7)(6.5)(15.3)(52.5)
Change in fair value of market risk benefits15.3 (10.9)(12.4)(4.4)(12.4)10.7 (8.3)(28.8)
Interest expense62.0 59.1 56.6 53.2 230.9 50.9 55.3 58.1 
Amortization of deferred acquisition costs and present value of future profits 67.4 68.6 69.9 72.1 278.0 74.2 74.9 76.8 
Goodwill and other asset impairment
— — 96.7 5.2 101.9 — — — 
Gain on extinguishment related to VIEs
(1.5)— — — (1.5)— — — 
Other operating costs and expenses275.3 271.1 270.4 302.8 1,119.6 275.3 276.4 240.9 
Total benefits and expenses976.3 1,033.5 1,152.5 1,031.7 4,194.0 981.2 1,125.5 859.6 
Income before income taxes27.8 118.0 36.2 111.4 293.4 48.4 159.7 226.4 
Income tax expense6.3 26.2 13.1 18.5 64.1 10.7 33.8 65.3 
Net income$21.5 $91.8 $23.1 $92.9 $229.3 $37.7 $125.9 $161.1 

Page 4


CNO FINANCIAL GROUP, INC.
FINANCIAL SUMMARY
(Dollars in millions, except per share data)
(Unaudited)

1Q2Q3Q4QYTD1Q2Q3Q
20252025202520252025202620262026
Insurance product margin (4)
Annuity margin$54.5 $54.8 $72.9 $56.4 $238.6 $58.5 $60.6 $87.9 
Health margin126.2 134.0 157.0 139.4 556.6 132.6 147.2 149.1 
Life margin68.2 63.6 70.6 70.0 272.4 65.8 71.2 96.0 
Total insurance product margin248.9 252.4 300.5 265.8 1,067.6 256.9 279.0 333.0 
Allocated expenses(161.2)(149.4)(151.0)(149.7)(611.3)(159.9)(152.9)(161.0)
Income from insurance products (8)87.7 103.0 149.5 116.1 456.3 97.0 126.1 172.0 
Fee income(0.8)0.8 (3.9)19.1 15.2 10.6 (1.2)(1.1)
Investment income not allocated to product lines (9)38.0 33.8 39.5 58.1 169.4 41.7 49.4 68.1 
Expenses not allocated to product lines(20.3)(25.3)(22.3)(19.8)(87.7)(19.4)(23.3)(18.8)
Operating earnings before taxes104.6 112.3 162.8 173.5 553.2 129.9 151.0 220.2 
Tax expense on operating income(23.5)(24.8)(35.6)(30.1)(114.0)(28.6)(31.5)(41.1)
Net operating income (10)81.1 87.5 127.2 143.4 439.2 101.3 119.5 179.1 
Net realized investment losses from disposals, impairments and change in allowance for credit losses
(13.2)(21.8)(8.8)(25.2)(69.0)(15.2)(13.6)(48.3)
Net change in market value of investments recognized in earnings6.4 3.4 5.8 (1.3)14.3 (7.5)(1.1)(16.4)
Fair value changes related to agent deferred compensation plan— — — (1.7)(1.7)— — 10.0 
Changes in fair value of embedded derivative liabilities and market risk benefits(69.6)25.2 (18.1)(1.5)(64.0)(42.4)34.6 69.7 
Expenses related to TechMod initiative
— (3.2)(7.2)(9.9)(20.3)(13.7)(9.7)(10.1)
Goodwill and other asset impairment
— — (96.7)(5.2)(101.9)— — — 
Net loss related to divested business— — — (17.3)(17.3)(1.9)(1.1)— 
Other(0.4)2.1 (1.6)— 0.1 (0.8)(0.4)1.3 
Net non-operating income (loss) before taxes(76.8)5.7 (126.6)(62.1)(259.8)(81.5)8.7 6.2 
Income tax expense:
On non-operating income (loss)17.2 (1.4)22.5 11.6 49.9 17.9 (2.3)(2.1)
Valuation allowance for deferred tax assets— — — — — — — (22.1)
Net non-operating income (loss)(59.6)4.3 (104.1)(50.5)(209.9)(63.6)6.4 (18.0)
Net income$21.5 $91.8 $23.1 $92.9 $229.3 $37.7 $125.9 $161.1 
Per diluted share
Net operating income$0.79 $0.87 $1.29 $1.47 $4.40 $1.05 $1.26 $1.90 
Net non-operating income (loss)(0.58)0.04 (1.05)(0.52)(2.10)(0.66)0.07 (0.19)
Net income$0.21 $0.91 $0.24 $0.95 $2.30 $0.39 $1.33 $1.71 

Page 5


CNO FINANCIAL GROUP, INC.
Insurance Operations
(Dollars in millions)
(Unaudited)

1Q2Q3Q4QYTD1Q2Q3Q
20252025202520252025202620262026
Insurance product margin (4)
Annuity:
Insurance policy income$9.8 $8.4 $10.7 $10.4 $39.3 $8.7 $10.2 $9.7 
Net investment income (5) (6)148.0 155.3 157.7 160.3 621.3 161.0 163.9 168.0 
Insurance policy benefits(10.3)(10.0)6.2 (10.9)(25.0)(11.6)(9.0)19.8 
Interest credited (6)(68.3)(73.4)(75.4)(76.4)(293.5)(71.8)(75.7)(79.5)
Amortization and non-deferred commissions(24.7)(25.5)(26.3)(27.0)(103.5)(27.8)(28.8)(30.1)
Annuity margin54.5 54.8 72.9 56.4 238.6 58.5 60.6 87.9 
Health:
Insurance policy income412.0 412.5 416.0 420.9 1,661.4 432.0 436.4 444.0 
Net investment income (5)75.1 75.9 75.4 75.5 301.9 74.5 75.8 76.1 
Insurance policy benefits(320.3)(313.3)(293.3)(314.9)(1,241.8)(331.2)(322.3)(327.5)
Amortization and non-deferred commissions(40.6)(41.1)(41.1)(42.1)(164.9)(42.7)(42.7)(43.5)
Health margin126.2 134.0 157.0 139.4 556.6 132.6 147.2 149.1 
Life:
Insurance policy income228.9 230.4 231.7 230.9 921.9 232.7 234.1 234.5 
Net investment income (5) (7)37.6 37.8 37.8 37.9 151.1 38.0 38.4 38.5 
Insurance policy benefits(138.1)(144.5)(142.6)(143.0)(568.2)(143.4)(139.3)(116.5)
Interest credited (7)(13.0)(13.8)(13.2)(13.7)(53.7)(13.7)(14.2)(14.0)
Amortization and non-deferred commissions(26.0)(27.6)(28.3)(29.1)(111.0)(29.5)(30.3)(30.9)
Advertising expense(21.2)(18.7)(14.8)(13.0)(67.7)(18.3)(17.5)(15.6)
Life margin68.2 63.6 70.6 70.0 272.4 65.8 71.2 96.0 
Total insurance product margin248.9 252.4 300.5 265.8 1,067.6 256.9 279.0 333.0 
Allocated expenses:
Branch office expenses(20.7)(15.9)(17.7)(13.8)(68.1)(20.0)(16.8)(18.7)
Other allocated expenses(140.5)(133.5)(133.3)(135.9)(543.2)(139.9)(136.1)(142.3)
Income from insurance products (8)87.7 103.0 149.5 116.1 456.3 97.0 126.1 172.0 
Fee income(0.8)0.8 (3.9)19.1 15.2 10.6 (1.2)(1.1)
Investment income not allocated to product lines (9)38.0 33.8 39.5 58.1 169.4 41.7 49.4 68.1 
Expenses not allocated to product lines(20.3)(25.3)(22.3)(19.8)(87.7)(19.4)(23.3)(18.8)
Operating earnings before taxes104.6 112.3 162.8 173.5 553.2 129.9 151.0 220.2 
Income tax expense on operating income(23.5)(24.8)(35.6)(30.1)(114.0)(28.6)(31.5)(41.1)
Net operating income (10)$81.1 $87.5 $127.2 $143.4 $439.2 $101.3 $119.5 $179.1 
Page 6


CNO FINANCIAL GROUP, INC.
Margin from Annuity Products
(Dollars in millions)
(Unaudited)

1Q2Q3Q4QYTD1Q2Q3Q
20252025202520252025202620262026
Annuity margin (4):
Fixed indexed annuities
Insurance policy income$7.2 $6.7 $6.8 $6.9 $27.6 $6.3 $7.7 $8.3 
Net investment income (5) (6)120.9 127.8 130.4 133.1 512.2 134.3 137.2 141.3 
Insurance policy benefits(5.5)(5.0)8.8 (5.2)(6.9)(4.6)(6.3)19.4 
Interest credited (6)(55.7)(60.8)(62.1)(63.7)(242.3)(60.2)(63.0)(67.1)
Amortization and non-deferred commissions(22.4)(23.3)(24.2)(24.7)(94.6)(25.6)(26.4)(27.3)
Margin from fixed indexed annuities$44.5 $45.4 $59.7 $46.4 $196.0 $50.2 $49.2 $74.6 
Average net insurance liabilities (11)$10,085.7 $10,543.4 $10,759.3 $10,941.4 $10,582.5 $11,104.1 $11,316.3 $11,700.9 
Margin/average net insurance liabilities (12)1.76 %1.72 %2.22 %1.70 %1.85 %1.81 %1.74 %2.55 %
Fixed interest annuities
Insurance policy income$0.5 $0.2 $0.8 $0.6 $2.1 $— $0.5 $1.2 
Net investment income (5)21.6 21.8 21.8 21.7 86.9 21.3 21.4 21.4 
Insurance policy benefits0.2 (0.1)0.5 0.1 0.7 (0.8)0.3 0.4 
Interest credited(12.1)(11.8)(12.5)(12.1)(48.5)(11.1)(12.2)(11.8)
Amortization and non-deferred commissions(2.1)(2.1)(2.1)(2.1)(8.4)(2.1)(2.2)(2.7)
Margin from fixed interest annuities$8.1 $8.0 $8.5 $8.2 $32.8 $7.3 $7.8 $8.5 
Average net insurance liabilities (11)$1,599.5 $1,591.7 $1,587.4 $1,587.2 $1,591.4 $1,580.4 $1,568.4 $1,561.5 
Margin/average net insurance liabilities (12)2.03 %2.01 %2.14 %2.07 %2.06 %1.85 %1.99 %2.18 %
Other annuities
Insurance policy income$2.1 $1.6 $3.0 $2.9 $9.6 $2.4 $2.0 $0.2 
Net investment income (5)5.5 5.6 5.6 5.5 22.2 5.4 5.3 5.3 
Insurance policy benefits(5.0)(5.0)(3.0)(5.8)(18.8)(6.2)(3.0)— 
Interest credited(0.5)(0.7)(0.9)(0.6)(2.7)(0.5)(0.5)(0.6)
Amortization and non-deferred commissions(0.2)(0.1)— (0.2)(0.5)(0.1)(0.2)(0.1)
Margin from other annuities$1.9 $1.4 $4.7 $1.8 $9.8 $1.0 $3.6 $4.8 
Average net insurance liabilities (11)$402.2 $398.5 $395.2 $392.1 $397.0 $388.9 $382.7 $375.1 
Margin/average net insurance liabilities (12)1.89 %1.41 %4.76 %1.84 %2.47 %1.03 %3.76 %5.12 %
Total annuity margin$54.5 $54.8 $72.9 $56.4 $238.6 $58.5 $60.6 $87.9 
Average net insurance liabilities (11)$12,087.4 $12,533.6 $12,741.9 $12,920.7 $12,570.9 $13,073.4 $13,267.4 $13,637.5 
Margin/average net insurance liabilities (12)1.80 %1.75 %2.29 %1.75 %1.90 %1.79 %1.83 %2.58 %
Page 7


CNO FINANCIAL GROUP, INC.
Margin from Health Products
(Dollars in millions)
(Unaudited)

1Q2Q3Q4QYTD1Q2Q3Q
20252025202520252025202620262026
Health margin (4):
Supplemental health
Insurance policy income$185.1 $185.0 $186.5 $188.2 $744.8 $190.4 $190.5 $191.8 
Net investment income (5)39.8 40.5 40.2 40.6 161.1 40.9 41.7 42.0 
Insurance policy benefits(131.6)(128.7)(101.6)(126.0)(487.9)(131.2)(133.3)(115.5)
Amortization and non-deferred commissions(27.7)(28.2)(28.0)(28.7)(112.6)(28.9)(28.8)(29.3)
Margin from supplemental health$65.6 $68.6 $97.1 $74.1 $305.4 $71.2 $70.1 $89.0 
Margin/insurance policy income35 %37 %52 %39 %41 %37 %37 %46 %
Medicare supplement
Insurance policy income$156.3 $155.9 $156.5 $158.3 $627.0 $165.9 $169.7 $174.3 
Net investment income (5)1.2 1.2 1.2 1.2 4.8 1.1 1.0 1.0 
Insurance policy benefits(120.0)(119.5)(127.2)(121.5)(488.2)(134.2)(124.6)(162.4)
Amortization and non-deferred commissions(9.4)(9.4)(9.3)(9.4)(37.5)(9.7)(9.6)(9.7)
Margin from Medicare supplement$28.1 $28.2 $21.2 $28.6 $106.1 $23.1 $36.5 $3.2 
Margin/insurance policy income18 %18 %14 %18 %17 %14 %22 %2 %
Long-term care
Insurance policy income$70.6 $71.6 $73.0 $74.4 $289.6 $75.7 $76.2 $77.9 
Net investment income (5)34.1 34.2 34.0 33.7 136.0 32.5 33.1 33.1 
Insurance policy benefits(68.7)(65.1)(64.5)(67.4)(265.7)(65.8)(64.4)(49.6)
Amortization and non-deferred commissions(3.5)(3.5)(3.8)(4.0)(14.8)(4.1)(4.3)(4.5)
Margin from long-term care$32.5 $37.2 $38.7 $36.7 $145.1 $38.3 $40.6 $56.9 
Margin/insurance policy income46 %52 %53 %49 %50 %51 %53 %73 %
Total health margin$126.2 $134.0 $157.0 $139.4 $556.6 $132.6 $147.2 $149.1 
Margin/insurance policy income31 %32 %38 %33 %34 %31 %34 %34 %
Page 8


CNO FINANCIAL GROUP, INC.
Margin from Life Products
(Dollars in millions)
(Unaudited)

1Q2Q3Q4QYTD1Q2Q3Q
20252025202520252025202620262026
Life margin (4):
Interest sensitive life
Insurance policy income$48.1 $48.0 $48.4 $48.9 $193.4 $49.4 $50.1 $50.3 
Net investment income (5) (7)13.9 13.9 14.0 14.1 55.9 14.2 14.3 14.5 
Insurance policy benefits(19.9)(20.7)(20.2)(18.9)(79.7)(21.0)(18.0)(19.3)
Interest credited (7)(12.9)(13.7)(13.1)(13.5)(53.2)(13.6)(14.0)(13.9)
Amortization and non-deferred commissions(5.1)(5.6)(5.6)(5.8)(22.1)(6.2)(6.0)(6.2)
Margin from interest sensitive life$24.1 $21.9 $23.5 $24.8 $94.3 $22.8 $26.4 $25.4 
Average net insurance liabilities (11)$1,096.1 $1,106.9 $1,126.7 $1,124.0 $1,113.4 $1,132.7 $1,146.2 $1,156.9 
Interest margin$1.0 $0.2 $0.9 $0.6 $2.7 $0.6 $0.3 $0.6 
Interest margin/average net insurance liabilities (12)0.36 %0.07 %0.32 %0.21 %0.24 %0.21 %0.10 %0.21 %
Underwriting margin$23.1 $21.7 $22.6 $24.2 $91.6 $22.2 $26.1 $24.8 
Underwriting margin/insurance policy income48 %45 %47 %49 %47 %45 %52 %49 %
Traditional life
Insurance policy income$180.8 $182.4 $183.3 $182.0 $728.5 $183.3 $184.0 $184.2 
Net investment income (5)23.7 23.9 23.8 23.8 95.2 23.8 24.1 24.0 
Insurance policy benefits(118.2)(123.8)(122.4)(124.1)(488.5)(122.4)(121.3)(97.2)
Interest credited(0.1)(0.1)(0.1)(0.2)(0.5)(0.1)(0.2)(0.1)
Amortization and non-deferred commissions(20.9)(22.0)(22.7)(23.3)(88.9)(23.3)(24.3)(24.7)
Advertising expense(21.2)(18.7)(14.8)(13.0)(67.7)(18.3)(17.5)(15.6)
Margin from traditional life$44.1 $41.7 $47.1 $45.2 $178.1 $43.0 $44.8 $70.6 
Margin/insurance policy income24 %23 %26 %25 %24 %23 %24 %38 %
Margin excluding advertising expense/insurance policy income36 %33 %34 %32 %34 %33 %34 %47 %
Total life margin$68.2 $63.6 $70.6 $70.0 $272.4 $65.8 $71.2 $96.0 




Page 9


CNO FINANCIAL GROUP, INC.
Collected Premiums and Insurance Policy Income
(Dollars in millions)
(Unaudited)

1Q2Q3Q4QYTD1Q2Q3Q
20252025202520252025202620262026
Collected premiums:
Annuity products
Fixed indexed annuities$388.0 $470.2 $425.3 $456.4 $1,739.9 $392.9 $487.3 $470.3 
Fixed interest annuities51.7 47.8 44.7 50.1 194.3 38.6 45.7 42.0 
Other annuities2.3 2.5 2.5 1.8 9.1 2.3 3.0 1.7 
Total annuity collected premiums442.0 520.5 472.5 508.3 1,943.3 433.8 536.0 514.0 
Health products
Supplemental health184.8 184.6 184.8 190.3 744.5 189.9 189.3 194.1 
Medicare supplement151.1 153.0 154.4 168.3 626.8 163.6 166.4 178.4 
Long-term care69.8 71.9 73.4 77.1 292.2 74.5 76.3 80.3 
Total health collected premiums405.7 409.5 412.6 435.7 1,663.5 428.0 432.0 452.8 
Life products
Interest-sensitive life62.9 63.6 64.4 64.9 255.8 65.7 67.3 65.8 
Traditional life181.5 181.9 182.6 182.7 728.7 184.1 182.0 184.2 
Total life collected premiums244.4 245.5 247.0 247.6 984.5 249.8 249.3 250.0 
Total collected premiums$1,092.1 $1,175.5 $1,132.1 $1,191.6 $4,591.3 $1,111.6 $1,217.3 $1,216.8 
Insurance policy income:
Annuity products
Fixed indexed annuities$7.2 $6.7 $6.8 $6.9 $27.6 $6.3 $7.7 $8.3 
Fixed interest annuities0.5 0.2 0.8 0.6 2.1 — 0.5 1.2 
Other annuities2.1 1.6 3.0 2.9 9.6 2.4 2.0 0.2 
Total annuity insurance policy income9.8 8.5 10.6 10.4 39.3 8.7 10.2 9.7 
Health products
Supplemental health185.1 185.0 186.5 188.2 744.8 190.4 190.5 191.8 
Medicare supplement156.3 155.9 156.5 158.3 627.0 165.9 169.7 174.3 
Long-term care70.6 71.6 73.0 74.4 289.6 75.7 76.2 77.9 
Total health insurance policy income412.0 412.5 416.0 420.9 1,661.4 432.0 436.4 444.0 
Life products
Interest-sensitive life 48.1 48.0 48.4 48.9 193.4 49.4 50.1 50.3 
Traditional life 180.8 182.4 183.3 182.0 728.5 183.3 184.0 184.2 
Total life insurance policy income228.9 230.4 231.7 230.9 921.9 232.7 234.1 234.5 
Total insurance policy income$650.7 $651.4 $658.3 $662.2 $2,622.6 $673.4 $680.7 $688.2 



Page 10


CNO FINANCIAL GROUP, INC.
Health and Life
New Annualized Premiums ("NAP")
(Dollars in millions)
(Unaudited)

1Q2Q3Q4QYTD1Q2Q3Q
20252025202520252025202620262026
Consumer Division
Health products:
Supplemental health$19.5 $22.0 $23.5 $26.0 $91.0 $21.4 $23.0 $21.0 
Medicare supplement12.0 12.2 13.3 31.8 69.3 18.3 18.5 18.7 
Long-term care10.2 10.1 12.4 12.1 44.8 10.2 10.5 12.7 
Total Consumer Division health NAP41.7 44.3 49.2 69.9 205.1 49.9 52.0 52.4 
Life products:
Interest sensitive life3.6 5.6 4.5 4.2 17.9 3.8 5.6 4.9 
Traditional life46.0 52.0 52.4 34.6 185.0 46.1 46.8 47.0 
Total Consumer Division life NAP49.6 57.6 56.9 38.8 202.9 49.9 52.4 51.9 
Total Consumer Division health and life NAP$91.3 $101.9 $106.1 $108.7 $408.0 $99.8 $104.4 $104.3 
Worksite Division
Health products:
Supplemental health$10.3 $11.7 $13.4 $13.1 $48.5 $11.2 $14.2 $13.5 
Life products:
Interest sensitive life4.1 6.3 5.6 6.7 22.7 6.4 8.8 8.7 
Traditional life— — — — — — 0.3 0.2 
Total Worksite Division life NAP4.1 6.3 5.6 6.7 22.7 6.4 9.1 8.9 
Total Worksite Division health and life NAP$14.4 $18.0 $19.0 $19.8 $71.2 $17.6 $23.3 $22.4 
Total NAP (both divisions)
Health products:
Supplemental health$29.8 $33.7 $36.9 $39.1 $139.5 $32.6 $37.2 $34.5 
Medicare supplement12.0 12.2 13.3 31.8 69.3 18.3 18.5 18.7 
Long-term care10.2 10.1 12.4 12.1 44.8 10.2 10.5 12.7 
Total health NAP52.0 56.0 62.6 83.0 253.6 61.1 66.2 65.9 
Life products:
Interest sensitive life 7.7 11.9 10.1 10.9 40.6 10.2 14.4 13.6 
Traditional life 46.0 52.0 52.4 34.6 185.0 46.1 47.1 47.2 
Total life NAP53.7 63.9 62.5 45.5 225.6 56.3 61.5 60.8 
Total NAP$105.7 $119.9 $125.1 $128.5 $479.2 $117.4 $127.7 $126.7 


Page 11


CNO FINANCIAL GROUP, INC.
Computation of Weighted Average Shares Outstanding
(Shares in thousands)

1Q2Q3Q4QYTD1Q2Q3Q
20252025202520252025202620262026
Basic
Shares outstanding, beginning of period101,619.0 99,893.9 97,319.0 95,841.0 101,619.0 94,484.3 93,795.3 92,697.0 
Weighted average share activity during the period:
Shares repurchased(1,106.8)(1,347.6)(731.7)(767.7)(4,554.0)(667.3)(653.5)(519.1)
Amounts related to employee benefit plans307.9 26.7 16.4 64.3 914.5 372.0 53.2 17.0 
Shares withheld for the payment of the exercise price and taxes related to employee benefit plans(77.3)(0.8)(0.9)(1.6)(216.1)(110.8)(0.6)(0.3)
Weighted average basic shares outstanding during the period100,742.8 98,572.2 96,602.8 95,136.0 97,763.4 94,078.2 93,194.4 92,194.6 
Basic shares outstanding, end of period99,893.9 97,319.0 95,841.0 94,484.3 94,484.3 93,795.3 92,697.0 91,705.5 
Diluted
Weighted average basic shares outstanding100,742.8 98,572.2 96,602.8 95,136.0 97,763.4 94,078.2 93,194.4 92,194.6 
Common stock equivalent shares related to:
Employee benefit plans2,327.1 1,814.0 1,950.6 2,141.6 2,058.4 2,060.6 1,757.5 2,058.5 
Weighted average diluted shares outstanding during the period103,069.9 100,386.2 98,553.4 97,277.6 99,821.8 96,138.8 94,951.9 94,253.1 
Diluted shares outstanding, end of period101,796.1 99,221.4 97,902.8 96,714.2 96,714.2 95,323.5 94,551.4 93,720.6 




Page 12


CNO FINANCIAL GROUP, INC.
Annuities - Account Value Rollforwards
(Dollars in millions)

1Q2Q3Q4QYTD1Q2Q3Q
20252025202520252025202620262026
Fixed indexed annuities
Policyholder account balances, beginning of period excluding contracts 100% ceded
$10,766.3 $10,952.1 $11,221.3 $11,433.0 $10,766.3 $11,633.0 $11,791.8 $12,091.3 
Issuances (funds collected from new business)383.7 463.0 418.7 445.3 1,710.7 385.0 474.7 461.3 
Premiums received (premiums collected from inforce business)4.0 7.4 6.6 10.9 28.9 8.5 12.3 8.8 
Policy charges(6.8)(6.9)(6.9)(6.7)(27.3)(6.9)(7.5)(8.1)
Surrenders and withdrawals(233.3)(221.6)(215.6)(249.3)(919.8)(260.3)(250.7)(251.5)
Benefit payments(72.7)(74.6)(72.6)(70.4)(290.3)(70.4)(78.1)(60.3)
Interest credited96.4 85.0 66.9 53.1 301.4 89.8 133.5 89.2 
Other14.5 16.9 14.6 17.1 63.1 13.1 15.3 14.6 
Policyholder account balances, end of period excluding contracts 100% ceded
$10,952.1 $11,221.3 $11,433.0 $11,633.0 $11,633.0 $11,791.8 $12,091.3 $12,345.3 
Fixed interest annuities
Policyholder account balances, beginning of period excluding contracts 100% ceded
$1,646.6 $1,640.7 $1,634.7 $1,635.1 $1,646.6 $1,637.5 $1,623.2 $1,614.1 
Issuances (funds collected from new business)50.9 47.1 44.2 49.5 191.7 38.1 45.1 41.6 
Premiums received (premiums collected from inforce business)0.7 1.0 0.2 0.3 2.2 1.1 0.4 (0.2)
Policy charges(0.4)(0.5)(0.5)(0.4)(1.8)(0.5)(0.4)(0.6)
Surrenders and withdrawals(41.4)(40.9)(35.4)(37.6)(155.3)(40.1)(38.8)(38.5)
Benefit payments(28.4)(25.2)(21.3)(22.0)(96.9)(24.5)(28.2)(18.2)
Interest credited12.7 12.5 13.1 12.6 50.9 11.6 12.7 12.3 
Other— — 0.1 — 0.1 — 0.1 — 
Policyholder account balances, end of period excluding contracts 100% ceded
$1,640.7 $1,634.7 $1,635.1 $1,637.5 $1,637.5 $1,623.2 $1,614.1 $1,610.5 
Total annuities
Policyholder account balances, beginning of period excluding contracts 100% ceded
$12,412.9 $12,592.8 $12,856.0 $13,068.1 $12,412.9 $13,270.5 $13,415.0 $13,705.4 
Issuances (funds collected from new business)434.6 510.1 462.9 494.8 1,902.4 423.1 519.8 502.9 
Premiums received (premiums collected from inforce business)4.7 8.4 6.8 11.2 31.1 9.6 12.7 8.6 
Policy charges(7.2)(7.4)(7.4)(7.1)(29.1)(7.4)(7.9)(8.7)
Surrenders and withdrawals(274.7)(262.5)(251.0)(286.9)(1,075.1)(300.4)(289.5)(290.0)
Benefit payments(101.1)(99.8)(93.9)(92.4)(387.2)(94.9)(106.3)(78.5)
Interest credited109.1 97.5 80.0 65.7 352.3 101.4 146.2 101.5 
Other14.5 16.9 14.7 17.1 63.2 13.1 15.4 14.6 
Policyholder account balances, end of period excluding contracts 100% ceded
$12,592.8 $12,856.0 $13,068.1 $13,270.5 $13,270.5 $13,415.0 $13,705.4 $13,955.8 

Page 13


CNO FINANCIAL GROUP, INC.
Consolidated Statutory Information of U.S. Based Insurance Subsidiaries (13)
(Dollars in millions)
(Unaudited)
1Q2Q3Q4QYTD1Q2Q3Q
202520252025 (a)202520252026 2026
2026 (b)
Net gain from operations before interest expense and federal income taxes$29.0 $37.7 $45.2 $95.3 $207.2 $37.4 $62.9 $42.9 
Interest expense on surplus debentures held by parent company15.5 15.7 29.4 15.3 75.9 14.4 14.5 14.8 
Net gain from operations before federal income taxes13.5 22.0 15.8 80.0 131.3 23.0 48.4 28.1 
Federal income tax expense (benefit)— — 20.9 61.6 82.5 — 13.0 6.2 
Net gain (loss) from operations before net realized capital gains (losses)13.5 22.0 (5.1)18.4 48.8 23.0 35.4 21.9 
Net realized capital losses
(1.2)(2.6)(11.1)(48.5)(63.4)(1.5)(16.4)(3.5)
Net income (loss)$12.3 $19.4 $(16.2)$(30.1)$(14.6)$21.5 $19.0 $18.4 
Capital and surplus$1,422.3 $1,417.8 $1,403.1 $1,405.3 $1,405.3 $1,399.1 $1,413.6 $1,418.3 
Asset valuation reserve (AVR)428.5 459.3 485.0 508.7 508.7 534.2 566.1 601.5 
Capital, surplus and AVR1,850.8 1,877.1 1,888.1 1,914.0 1,914.0 1,933.3 1,979.7 2,019.8 
Interest maintenance reserve (IMR)331.5 315.8 298.3 252.6 252.6 246.2 243.6 226.9 
Total statutory capital, surplus, AVR & IMR$2,182.3 $2,192.9 $2,186.4 $2,166.6 $2,166.6 $2,179.5 $2,223.3 $2,246.7 
Risk-based capital ratio379 %378 %380 %380 %380 %375 %377 %374 %
___________
(a)    Statutory capital and surplus, IMR and risk-based capital ratio are adjusted to reflect equal and offsetting timing impacts associated with the reinsurance transaction executed with our Bermuda reinsurance company in October 2025.
(b)     Such amounts are preliminary as the statutory basis financial statements of our U.S. based insurance subsidiaries for 3Q26 will be filed with the respective insurance regulators on or about November 14, 2026.

Page 14


CNO FINANCIAL GROUP, INC.
Investment Income Not Allocated to Product Lines (9)
(Dollars in millions)
(Unaudited)
1Q2Q3Q4QYTD1Q2Q3Q
20252025202520252025202620262026
Investment income not allocated:
Excluding variable components:
From general account assets$28.0 $24.1 $20.6 $32.3 $105.0 $23.4 $23.5 $24.3 
Other investment income10.9 6.6 1.8 3.2 22.5 3.2 3.0 1.9 
Spread income:
Federal Home Loan Bank ("FHLB") program:
Investment income
35.4 36.6 40.6 37.8 150.4 36.9 42.6 46.6 
Interest expense (a)
(26.0)(27.7)(29.7)(27.8)(111.2)(25.9)(30.3)(33.3)
Net spread income on FHLB program9.4 8.9 10.9 10.0 39.2 11.0 12.3 13.3 
Funding agreement-backed notes ("FABN") program:
Investment income
34.3 36.9 37.6 42.9 151.7 46.5 49.3 52.3 
Expenses (a)(b)
(27.9)(27.7)(29.1)(32.9)(117.6)(36.7)(37.5)(40.7)
Net spread income on FABN program6.4 9.2 8.5 10.0 34.1 9.8 11.8 11.6 
Interest expense on corporate debt (a)
(27.2)(24.6)(20.3)(20.4)(92.5)(20.3)(20.4)(20.4)
Interest expense on financing arrangements (a)
(1.0)(1.0)(0.8)(0.9)(3.7)(0.7)(0.7)(0.6)
Total excluding variable components 26.5 23.2 20.7 34.2 104.6 26.4 29.5 30.1 
Variable components:
Net income from assets supporting deferred compensation plans:
Investment income
(2.1)15.0 11.3 4.6 28.8 (5.9)17.5 (0.3)
Expenses (a)
2.8 (14.9)(10.4)(4.2)(26.7)4.0 (19.9)(0.8)
Net income from assets supporting deferred compensation plans
0.7 0.1 0.9 0.4 2.1 (1.9)(2.4)(1.1)
Alternative investment income (loss):
Total alternative income
12.9 11.7 15.8 24.1 64.5 17.7 21.2 37.4 
Allocated to product lines(6.0)(6.0)(5.9)(5.0)(22.9)(5.2)(6.1)(6.2)
Allocated to FABN program— (0.7)0.1 (0.1)(0.7)(0.8)(1.1)(1.7)
Excess alternative investment income (loss)6.9 5.0 10.0 19.0 40.9 11.7 14.0 29.5 
Trading account income
1.6 2.0 1.2 0.9 5.7 1.2 1.5 0.8 
Hedge variance related to fixed indexed products (a)
(0.5)1.5 — (0.2)0.8 (0.1)(0.7)(0.7)
Impact of annual option forfeitures related to fixed indexed annuity surrenders (a)
3.5 1.5 3.8 5.6 14.4 4.2 5.4 4.9 
Impacts of change in projected cash flows, prepayment and call income and other
(0.7)0.5 2.9 (1.8)0.9 0.2 2.1 4.6 
Total variable components11.5 10.6 18.8 23.9 64.8 15.3 19.9 38.0 
Total investment income not allocated to product lines $38.0 $33.8 $39.5 $58.1 $169.4 $41.7 $49.4 $68.1 
Reconciliation to net investment income:
Total investment income not allocated to product lines$38.0 $33.8 $39.5 $58.1 $169.4 $41.7 $49.4 $68.1 
Amounts allocated to products260.7 268.9 271.0 273.7 1,074.3 273.5 278.1 282.6 
Total allocated and not allocated to products investment income
298.7 302.7 310.5 331.8 1,243.7 315.2 327.5 350.7 
Investment income on variable interest entities reported as non-operating income
7.2 7.0 4.5 4.6 23.3 4.0 4.3 4.9 
Add back amounts reported as benefits and expenses76.3 92.9 86.5 80.8 336.5 75.5 104.1 91.6 
Change in market values of the underlying options supporting fixed indexed products(70.7)81.1 98.2 11.3 119.9 (64.6)161.1 0.4 
Net investment income$311.5 $483.7 $499.7 $428.5 $1,723.4 $330.1 $597.0 $447.6 
___________
(a)    Amounts reported as benefits and expenses
(b)    Comprised of interest credited and amortization of deferred acquisition costs
Page 15


CNO FINANCIAL GROUP, INC.
Investment Income Allocated to Product Lines (5)
(Dollars in millions)
(Unaudited)
1Q2Q3Q4QYTD1Q2Q3Q
20252025202520252025202620262026
Average net insurance liabilities (11)
Annuity:
Fixed indexed annuities$10,085.7 $10,543.4 $10,759.3 $10,941.4 $10,582.5 $11,104.1 $11,316.3 $11,700.9 
Fixed interest annuities1,599.5 1,591.7 1,587.4 1,587.2 1,591.4 1,580.4 1,568.4 1,561.5 
Other annuities402.2 398.5 395.2 392.1 397.0 388.9 382.7 375.1 
Total annuity average net insurance liabilities (11)12,087.4 12,533.6 12,741.9 12,920.7 12,570.9 13,073.4 13,267.4 13,637.5 
Health:
Supplemental health3,387.4 3,405.3 3,405.2 3,407.0 3,401.2 3,425.9 3,445.3 3,456.2 
Medicare supplement113.1 102.0 95.7 95.6 101.6 94.3 84.6 88.6 
Long-term care2,695.7 2,694.5 2,691.0 2,689.1 2,692.6 2,687.9 2,684.2 2,674.5 
Total health average net insurance liabilities (11)6,196.2 6,201.8 6,191.9 6,191.7 6,195.4 6,208.1 6,214.1 6,219.3 
Life:
Interest sensitive1,096.1 1,106.9 1,126.7 1,124.0 1,113.4 1,132.7 1,146.2 1,156.9 
Traditional2,020.3 2,011.9 2,002.5 2,006.7 2,010.4 2,016.6 2,013.4 1,997.4 
Total life average net insurance liabilities (11)3,116.4 3,118.8 3,129.2 3,130.7 3,123.8 3,149.3 3,159.6 3,154.3 
Total average net insurance liabilities (11)$21,400.0 $21,854.2 $22,063.0 $22,243.1 $21,890.1 $22,430.8 $22,641.1 $23,011.1 
Average yield on allocated investments
Annuity:
Fixed indexed annuities4.79 %4.85 %4.85 %4.87 %4.84 %4.84 %4.85 %4.83 %
Fixed interest annuities5.40 %5.48 %5.49 %5.47 %5.46 %5.39 %5.46 %5.48 %
Other annuities5.47 %5.62 %5.67 %5.61 %5.59 %5.55 %5.54 %5.65 %
Average yield on investments allocated to annuities4.90 %4.95 %4.95 %4.96 %4.94 %4.93 %4.94 %4.93 %
Health:
Supplemental health4.70 %4.76 %4.72 %4.77 %4.74 %4.78 %4.84 %4.86 %
Medicare supplement4.24 %4.71 %5.02 %5.02 %4.72 %4.67 %4.73 %4.51 %
Long-term care5.06 %5.08 %5.05 %5.01 %5.05 %4.84 %4.93 %4.95 %
Average yield on investments allocated to health products4.85 %4.90 %4.87 %4.88 %4.87 %4.80 %4.88 %4.89 %
Life:
Interest sensitive5.07 %5.02 %4.97 %5.02 %5.02 %5.01 %4.99 %5.01 %
Traditional4.69 %4.75 %4.75 %4.74 %4.74 %4.72 %4.79 %4.81 %
Average yield on investments allocated to life products4.83 %4.85 %4.83 %4.84 %4.84 %4.83 %4.86 %4.88 %
Total average yield4.87 %4.92 %4.91 %4.92 %4.91 %4.88 %4.91 %4.91 %
Allocated investment income
Annuity:
Fixed indexed annuities$120.9 $127.8 $130.4 $133.1 $512.2 $134.3 $137.2 $141.3 
Fixed interest annuities21.6 21.8 21.8 21.7 86.9 21.3 21.4 21.4 
Other annuities5.5 5.6 5.6 5.5 22.2 5.4 5.3 5.3 
Total investment income allocated to annuities148.0 155.2 157.8 160.3 621.3 161.0 163.9 168.0 
Health:
Supplemental health39.8 40.5 40.2 40.6 161.1 40.9 41.7 42.0 
Medicare supplement1.2 1.2 1.2 1.2 4.8 1.1 1.0 1.0 
Long-term care34.1 34.2 34.0 33.7 136.0 32.5 33.1 33.1 
Total investment income allocated to health products75.1 75.9 75.4 75.5 301.9 74.5 75.8 76.1 
Life:
   Interest sensitive13.9 13.9 14.0 14.1 55.9 14.2 14.3 14.5 
Traditional23.7 23.9 23.8 23.8 95.2 23.8 24.1 24.0 
Total investment income allocated to life products37.6 37.8 37.8 37.9 151.1 38.0 38.4 38.5 
Total allocated investment income$260.7 $268.9 $271.0 $273.7 $1,074.3 $273.5 $278.1 $282.6 
Page 16


CNO FINANCIAL GROUP, INC.
Other Investment Data
(Dollars in millions)
(Unaudited)
1Q2Q3Q4Q1Q2Q3Q
2025202520252025202620262026
Average book value of invested assets and cash$30,755.7 $30,732.5 $30,878.3 $31,461.7 $32,039.4 $32,711.7 $33,450.5 
New money rate (14)6.43 %6.42 %6.20 %6.11 %6.08 %6.16 %6.24 %
Book yield (15)4.81 %4.83 %4.83 %4.84 %4.86 %4.88 %4.92 %
Earned yield (16)4.71 %4.73 %4.77 %5.04 %4.79 %4.88 %5.16 %
Fair value of invested assets and cash
$28,900.6 $28,899.5 $29,998.9 $30,601.7 $30,740.9 $31,654.9 $30,997.0 
Equity returns credited to policyholders(70.2)79.5 98.2 11.5 (64.5)161.8 1.1 

CNO FINANCIAL GROUP, INC.
3Q26 Significant Items
(Dollars in millions, except per share amounts)
(Unaudited)

The table below summarizes the financial impact of significant items on our net operating income for the three months ended September 30, 2026. Management believes that identifying the impact of these items enhances the understanding of our operating results.

Three months ended
September 30, 2026
Actual resultsSignificant itemsExcluding significant
items
Insurance product margin (4)
Annuity margin$87.9 $(20.5)(a)$67.4 
Health margin149.1 (7.8)(a)141.3 
Life margin96.0 (28.0)(a)68.0 
Total insurance product margin333.0 (56.3)276.7 
Allocated expenses(161.0)— (161.0)
Income from insurance products (5)172.0 (56.3)115.7 
Fee income(1.1)— (1.1)
Investment income not allocated to product lines (9)68.1 — 68.1 
Expenses not allocated to product lines(18.8)— (18.8)
Operating earnings before taxes220.2 (56.3)163.9 
Income tax (expense) benefit on operating income(41.1)11.4 (29.7)
Net operating income (10)$179.1 $(44.9)$134.2 
Net operating income per diluted share$1.90 $(0.48)$1.42 

(a)Comprised of $56.3 million of the net favorable impact arising from our comprehensive annual actuarial review.

















Page 17


3Q25 Significant Items
(Dollars in millions, except per share amounts)
(Unaudited)

The table below summarizes the financial impact of significant items on our net operating income for the three months ended September 30, 2025. Management believes that identifying the impact of these items enhances the understanding of our operating results.
Three months ended
September 30, 2025
Actual resultsSignificant itemsExcluding significant
items
Insurance product margin (4)
Annuity margin$72.9 $(16.6)(a)$56.3 
Health margin157.0 (21.1)(a)135.9 
Life margin70.6 (3.6)(a)67.0 
Total insurance product margin300.5 (41.3)259.2 
Allocated expenses(151.0)— (151.0)
Income from insurance products (5)149.5 (41.3)108.2 
Fee income(3.9)— (3.9)
Investment income not allocated to product lines (9)39.5 — 39.5 
Expenses not allocated to product lines(22.3)— (22.3)
Operating earnings before taxes162.8 (41.3)121.5 
Income tax (expense) benefit on operating income(35.6)9.1 (26.5)
Net operating income (10)$127.2 $(32.2)$95.0 
Net operating income per diluted share$1.29 $(0.33)$0.96 
___________
(a)Comprised of $41.3 million of the net favorable impact arising from our comprehensive annual actuarial review.

1Q25 Significant Items
(Dollars in millions, except per share amounts)
(Unaudited)

The table below summarizes the financial impact of significant items on our net operating income for the three months ended March 31, 2025. Management believes that identifying the impact of these items enhances the understanding of our operating results.

Three months ended
March 31, 2025
Actual resultsSignificant itemsExcluding significant
items
Insurance product margin (4)
Annuity margin$54.5 $— $54.5 
Health margin126.2 — 126.2 
Life margin68.2 (6.8)(a)61.4 
Total insurance product margin248.9 (6.8)242.1 
Allocated expenses(161.2)— (161.2)
Income from insurance products (5)87.7 (6.8)80.9 
Fee income(0.8)— (0.8)
Investment income not allocated to product lines (9)38.0 — 38.0 
Expenses not allocated to product lines(20.3)— (20.3)
Operating earnings before taxes104.6 (6.8)97.8 
Income tax (expense) benefit on operating income(23.5)1.5 (22.0)
Net operating income (10)$81.1 $(5.3)$75.8 
Net operating income per diluted share$0.79 $(0.05)$0.74 
___________
(a)Comprised of $6.8 million of the favorable impact of an out-of-period adjustment which decreased reserves.




Page 18


Notes

(1)Excludes accumulated other comprehensive income (loss). Management believes this non-GAAP measure is useful because it removes the volatility that arises from changes in the unrealized appreciation (depreciation) of our investments.
(2)Shareholders' equity divided by common shares outstanding.
(3)Book value per diluted share reflects the potential dilution that could occur if outstanding stock options were exercised and restricted stock and performance units were vested. The dilution from options, restricted shares and performance units is calculated using the treasury stock method. Under this method, we assume the proceeds from the exercise of the options (or the unrecognized compensation expense with respect to restricted stock and performance units) will be used to purchase shares of our common stock at the closing market price on the last day of the period.
(4)Insurance product margin is management’s measure of the profitability of its annuity, health and life product lines’ performance and consists of insurance policy income plus allocated investment income less insurance policy benefits, interest credited, commissions, advertising expense and amortization of acquisition costs. See note (8) for definition of income from insurance products.
(5)Net investment income is allocated to the product lines using the book yield of investments backing the block of business, which is applied to the average insurance liabilities, net of insurance intangibles, for the block in each period. See note (11) for definition of net insurance liabilities.
(6)Excludes the change in market values of the underlying options supporting the fixed indexed annuity products and corresponding amount credited to policyholder account balances. Such amounts were $(63.5) million, $70.4 million, $89.4 million, $10.2 million, $(58.7) million, $146.8 million and $0.0 million in 1Q25, 2Q25, 3Q25, 4Q25, 1Q26, 2Q26 and 3Q26, respectively.
(7)Excludes the change in market values of the underlying options supporting the fixed indexed life products and corresponding amount credited to policyholder account balances. Such amounts were $(6.7) million, $9.1 million, $8.8 million, $1.3 million, $(5.8) million, $15.0 million and $1.1 million in 1Q25, 2Q25, 3Q25, 4Q25, 1Q26, 2Q26 and 3Q26, respectively.
(8)Income from insurance products is the sum of the insurance product margins of the annuity, health and life product lines, less expenses allocated to the insurance product lines. It excludes the income from our fee income business, investment income not allocated to product lines, net expenses not allocated to product lines (primarily holding company expenses) and income taxes. Management believes this information provides an additional understanding of the business and a more meaningful analysis of results of our insurance product lines. Income from insurance products, a non-GAAP measure, is a component of net operating income, which is reconciled to net income on page 5 of this Quarterly Financial Supplement.
(9)Investment income not allocated to product lines represents net investment income less: (i) equity returns credited to policyholder account balances; (ii) the investment income allocated to our product lines; (iii) interest expense on notes payable, investment borrowings and financing arrangements; (iv) expenses related to the FABN program; and (v) certain expenses related to benefit plans that are offset by special-purpose investment income; plus (vi) the impact of annual option forfeitures related to fixed indexed annuity surrenders. Investment income not allocated to product lines includes investment income on investments in excess of amounts allocated to product lines, investments held by our holding companies, the spread we earn from our FHLB investment borrowing and FABN programs and variable components of investment income (including call and prepayment income, adjustments to returns on structured securities due to cash flow changes, income (loss) from company-owned life insurance ("COLI") and alternative investment income not allocated to product lines), net of interest expense on corporate debt and financing arrangements. The spread earned from our FHLB investment borrowing and FABN programs includes the investment income on the matched assets less: (i) interest on investment borrowings related to the FHLB investment borrowing program; (ii) interest credited on funding agreements; and (iii) amortization of deferred acquisition costs related to the FABN program.

(10)Management believes that an analysis of net income applicable to common stock before the following items (each net of tax, except as noted) is important to evaluate the financial performance of the Company, and is a key measure commonly used in the life insurance industry: (i) net realized investment gains or losses from disposals, impairments and the change in allowance for credit losses; (ii) net change in market value of investments recognized in earnings; (iii) changes in fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities; (iv) fair value changes related to the agent deferred compensation plan; (v) gains or losses related to material reinsurance transactions; (vi) loss on extinguishment of debt; (vii) changes in the valuation allowance for deferred tax assets and other tax items; (viii) costs related to our three-year project to modernize certain elements of our technology ("TechMod") that are incremental to normal spend and will not recur following implementation; (ix) goodwill and other asset impairment expenses; (x) gains or losses related to divested business; and (xi) other non-operating items including earnings attributable to variable interest entities (collectively, "net operating income," a non-GAAP financial measure). The income tax expense or benefit allocated to the items included in net non-operating income (loss) represents the current and deferred income tax expense or benefit allocated to the items included in non-operating earnings. Management believes this information provides a better understanding of the business and a more meaningful analysis of results of our insurance product lines. The table above reconciles the non-GAAP measure to the corresponding GAAP measure.

(11)Net insurance liabilities for the purpose of allocating investment income to product lines are equal to: (i) policyholder account values for interest sensitive products; (ii) total reserves before the fair value adjustments reflected in accumulated other comprehensive income (loss), if applicable, for all other products; less (iii) amounts related to reinsured business; (iv) deferred acquisition costs; (v) the present value of future profits; and (vi) the value of unexpired options credited to insurance liabilities.
(12)Margin/average net insurance liabilities for quarterly periods is calculated by annualizing the quarters' margin divided by the average net insurance liabilities.
(13)Based on statutory accounting practices prescribed or permitted by regulatory authorities for CNO Financial's U.S. based insurance subsidiaries after appropriate elimination of intercompany accounts among such subsidiaries. Such accounting practices differ from accounting principles generally accepted in the United States of America.
Page 19


(14)The new money rate is for the investments purchased during the period to support our insurance products and capital. It excludes the new money rate on investments purchased with investment borrowings under our FHLB and FABN programs and investments purchased by the variable interest entities.
(15)Book yield on fixed maturity investments, excluding investments held in the: (i) FHLB and FABN programs; and (ii) the investments held by the variable interest entities.
(16)Earned yield is the investment income earned during the period divided by the average book value of the investment portfolio, excluding: (i) investments held in the FHLB and FABN programs; and (ii) the investments held by the variable interest entities.
Page 20
1 Unless otherwise specified, comparisons in this presentation are between 3Q25 and 3Q26. Third Quarter 2026 Financial and operating results for the period ended September 30, 2026 October 29, 2026

 

2 Certain statements made in this presentation should be considered forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These include statements about future results of operations and capital plans. We caution investors that these forward-looking statements are not guarantees of future performance, and actual results may differ materially. Investors should consider the important risks and uncertainties that may cause actual results to differ, including those included in our press release issued on October 29, 2026, our Quarterly Reports on Form 10-Q, our Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission. We assume no obligation to update this presentation, which speaks as of today’s date. Forward-Looking Statements This presentation contains financial measures that differ from the comparable measures under Generally Accepted Accounting Principles (GAAP). Reconciliations between those non-GAAP measures and the comparable GAAP measures are included in the Appendix, or on the page such measure is presented. While management believes the measures are useful to enhance understanding and comparability of our financial results, these non-GAAP measures should not be considered substitutes for the most directly comparable GAAP measures. Additional information concerning non-GAAP measures is included in our periodic filings with the Securities and Exchange Commission that are available in the “Investors – Financials – SEC Filings” section of CNO’s website, CNOinc.com. Non-GAAP Measures IMPORTANT LEGAL INFORMATION

 

3 OUR PURPOSE We secure the future of middle-income America. OUR MISSION We secure the future of middle-income America by providing insurance and financial services that help protect their health, income and retirement needs, while building enduring value for all our stakeholders.

 

4 1 A non-GAAP measure. See the Appendix for a reconciliation to the corresponding GAAP measure. Operational Highlights Financial Highlights QUARTER IN REVIEW Strong results continue; Raising full-year operating EPS guidance  Operating earnings per share (EPS)1 up 47%; Year-to-date up 43% – Sales momentum driving profitable growth – Continued strong underwriting and net investment income (NII) results – Operating return on equity (ROE) of 14.1%, excluding significant items1  In October, executed 3rd reinsurance transaction with Bermuda affiliate  Robust total capital position  Returned $77 million to shareholders  Book value per diluted share excluding AOCI1 of $41.29, up 8%  17th consecutive quarter of sales growth – Sales growth in most product categories – Career field agents delivered growth in every major product line across both Divisions – Broad-based momentum across asset accumulation products  15th consecutive quarter of growth in producing agent count (PAC)  Durable competitive moat generating consistent and repeatable sales growth

 

5 2026 3Q 4Q FY 1Q 2Q 3Q vs 3Q25 New Annualized Premiums1 $125.1 $128.5 $479.2 $117.4 $127.7 $126.7 1.3% Consumer 106.1 108.7 408.0 99.8 104.4 104.3 -1.7% Worksite 19.0 19.8 71.2 17.6 23.3 22.4 17.9% Annuity Collected Premiums $472.5 $508.3 $1,943.3 $433.8 $536.0 $514.0 8.8% Fee Revenue1,2 $33.0 $71.4 $185.3 $42.8 $18.5 $14.4 n/m Consumer 26.2 71.4 163.7 42.8 18.5 14.4 -45.0% Worksite 6.8 -- 21.6 -- -- -- n/m Policyholder and Client Assets $18,108 $18,307 -- $18,497 $19,395 $19,753 9.1% Annuity Account Values 13,068 13,271 -- 13,415 13,705 13,956 6.8% Client Assets in BD and Advisory 1 5,040 5,036 -- 5,082 5,690 5,797 15.0% Producing Agent Counts (PAC) 1 4,928 5,016 -- 4,967 5,125 5,123 4.0% Consumer 4,518 4,612 -- 4,566 4,697 4,689 3.8% Worksite 410 404 -- 401 428 434 5.9% Average Book Value of Investments & Cash $30,878 $31,462 -- $32,039 $32,712 $33,451 8.3% Average Yield on Allocated Investments 4.91% 4.92% 4.91% 4.88% 4.91% 4.91% 0 bps New Money Rate 6.20% 6.11% -- 6.08% 6.16% 6.24% 4 bps Book Value per Diluted Share x AOCI 3 $38.10 $38.81 -- $38.98 $39.92 $41.29 8.4% 3-year CAGR 6.1% 6.8% -- 7.0% 7.3% 7.0% -- Change2025 IN V E S T M E N T S & C A P IT A L P R O D U C T IO N D IS T R IB U T IO N GROWTH SCORECARD Sustained and repeatable growth (dollars in millions) 1 See page 25 for a glossary of terms and definitions. 2 Beginning in 4Q25, Worksite Division fee services revenue will be reported as non-operating due to the previously announced exit of the business. 3 Excluding accumulated other comprehensive income (loss) (a non-GAAP measure). See the Appendix for a reconciliation to the corresponding GAAP measure. n/m Result not meaningful following the reclassification of Worksite fee revenue to non-operating results in 4Q25.

 

6 CONSUMER DIVISION UPDATE 16th consecutive quarter of sales growth1; Continued strength in career field agent channel  PAC up 4%; 15th consecutive quarter of growth – Strong agent productivity and retention – Registered agents up 4%  Total Medicare policies sold up 20%  NAP generated from non-TV lead sources represented 71% of total D2C sales  Career field agent NAP up 13%  Health NAP up 7% – Medicare Supplement NAP up 41% – LTC NAP up 2%  Annuity collected premiums up 9% – Account values up 7%  Record client assets in brokerage and advisory, up 15% – Total accounts up 13% Operational Highlights Distribution Highlights 1 See page 25 for a glossary of terms and definitions.

 

7 WORKSITE DIVISION UPDATE 18th consecutive quarter of sales growth1; 8th consecutive quarter of double-digit growth  Career field agent NAP up 29%  Life and Health NAP up 18% – Life NAP up 59% – Hospital Indemnity NAP up 16% – Accident NAP up 16%  Record PAC, up 6%; 17th consecutive quarter of growth – Productivity up across all cohorts  NAP from new clients up 168% Operational Highlights Distribution Highlights 1 See page 25 for a glossary of terms and definitions.

 

8 1 A non-GAAP measure. See the Appendix for a reconciliation to the corresponding GAAP measure. Net operating earnings per share1 (dollars in millions, except per share amounts); TTM = trailing twelve months Earnings Results FINANCIAL HIGHLIGHTS Excluding significant items Operating EPS excluding significant items1 up 48%; Year-to-date up 45% Highlights $399.9$295.8$179.1$127.2Net operating income1 $355.0$258.3$134.2$95.0 Net operating income excluding significant items1 $324.7$136.4$161.1$23.1Net Income 95.1100.794.398.6 Weighted average shares outstanding (in millions) $1.29 $1.90 $2.94 $4.20 3Q25 3Q26 YTD 2025 YTD 2026 $0.96 $1.42 $2.57  Operating EPS1 of $1.90, up 47% — Net favorable results from annual actuarial review  Operating EPS1 of $1.42, up 48% excluding significant items — Strong sales contributing to growth in insurance product margin and net investment income — Improvement in net investment income not allocated led by alternative investment returns — Favorable expenses  Announced 3rd reinsurance transaction with Bermuda affiliate  $60 million of share repurchases — 4% reduction in weighted average diluted shares outstanding  Maintained robust total capital position  TTM operating ROE1 of 15.4%; 14.1% excluding significant items $3.73

 

9 (dollars in millions) Insurance Product Margin Excluding Significant Items1 1 Excludes impacts from the annual actuarial review. See the Appendix for a reconciliation to the corresponding GAAP measure and a breakdown of impacts by major product category. INSURANCE PRODUCT MARGIN Total margin up 7%, primarily driven by continued sales momentum 3Q25 4Q25 1Q26 2Q26 3Q26 Annuity $56.3 $56.4 $58.5 $60.6 $67.4 Fixed Indexed Annuities $45.9 $46.4 $50.2 $49.2 $53.4 Fixed Interest Annuities $8.5 $8.2 $7.3 $7.8 $9.2 Other Annuities $1.9 $1.8 $1.0 $3.6 $4.8 Health $135.9 $139.4 $132.6 $147.2 $141.3 Supplemental Health $72.3 $74.1 $71.2 $70.1 $72.8 Medicare Supplement $30.4 $28.6 $23.1 $36.5 $29.9 Long-term Care $33.2 $36.7 $38.3 $40.6 $38.6 Life $67.0 $70.0 $65.8 $71.2 $68.0 Interest Sensitive Life $20.7 $24.8 $22.8 $26.4 $23.0 Traditional Life $46.3 $45.2 $43.0 $44.8 $45.0 Total Margin $259.2 $265.8 $256.9 $279.0 $276.7 Annuity margin  Fixed Indexed Annuities (FIA) – growth in the block and go-forward income pattern change from annual actuarial review  Other Annuities – favorable reserve releases on closed block policies Health margin  Supplemental Health – growth in the block offset by less favorable morbidity  Medicare Supplement – Higher morbidity, partially offset by growth in the block and implementation of rate increases  LTC – growth in the block and lower morbidity Life margin  ISL – growth in the block and lower mortality  Traditional Life – higher nondeferrable advertising expense Annual actuarial review  Current period net benefit of $56.3 million, reflecting broad-based favorable experience, partially offset by Medicare Supplement  Quarterly go-forward income pattern changes  FIA +$3.5mm, Med Supp +$1mm Highlights

 

10 1 Reflects sum of allocated and non-allocated investment income. Refer to pages 15-17 of the financial supplement for more information on the components of net investment income. 2 Net insurance liabilities for the purpose of allocating investment income to product lines are equal to: (i) policyholder account values for interest sensitive products; (ii) total reserves before the fair value adjustments reflected in accumulated other comprehensive income (loss), if applicable, for all other products; less (iii) amounts related to reinsured business; (iv) deferred acquisition costs; (v) the present value of future profits; and (vi) the value of unexpired options credited to insurance liabilities.  Average yield on allocated investments of 4.91% in 3Q26, unchanged from 3Q25  Average net insurance liabilities2 up 4.3%  Favorable net investment income on alternative assets  Higher FHLB and FABN funding and margins Investment Income Allocated to Product Lines Investment Income Not Allocated to Product Lines Annuity Health Life Not allocated $- $100.0 $200.0 $300.0 3Q25 3Q26 INVESTMENT RESULTS (dollars in millions)  New money rate of 6.24% in 3Q26, 15th consecutive quarter over 6%  Average book value of invested assets up 8.3%  Earned yield of 5.16% in 3Q26 vs. 4.77% in 3Q25 $271.0 $282.6 $- $100.0 $200.0 $300.0 3Q25 3Q26 Total net investment income1 up 13%; 12th consecutive quarter of growth Total Net Investment Income1 $39.5 $68.1 $- $100.0 $200.0 $300.0 3Q25 3Q26 $350.7 $310.5

 

11 Debt to Capital2 Consolidated Risk Based Capital (RBC) Ratio1 Holding Company Liquidity 1 The ratio of the combined capital of the insurance companies to the minimum amount of capital appropriate to support the overall business operations, as determined based on the methodology developed by the National Association of Insurance Commissioners. 2 Excluding accumulated other comprehensive income (loss) (a non-GAAP measure). See the Appendix for a reconciliation to the corresponding GAAP measure. (dollars in millions)  Managing RBC Ratio in the range of 360% – 390%  RBC ratio variability expected in periods of market volatility  Target leverage of 25% - 28%  Debt covenant ceiling of 35%  $168 million in debt capacity to top of target leverage range  Target minimum holding company liquidity of $150 million  Liquidity backstopped by $250 million undrawn revolver  Staggered debt maturities in 2029 and 2034 CAPITAL AND LIQUIDITY OVERVIEW Robust total capital position Debt to capital2 excluding $500 million note that matured May 2025 $372 $351 $280 $233 $231 2024 2025 1Q26 2Q26 3Q26 32.1% 26.2% 26.4% 26.1% 25.7% 2024 2025 1Q26 2Q26 3Q26 25.6% 383% 380% 375% 377% 374% 2024 2025 1Q26 2Q26 3Q26

 

12 GUIDANCE Guidance excludes significant items Raising full-year operating EPS guidance 9% at the midpoint 2026 Operating Earnings 2026 Free Cash Flow / Excess Capital  $5.05 – $5.15 operating EPS  18.6% – 18.8% expense ratio  ~20.5% effective tax rate  $220 – $240 million free cash flow  360% – 390% RBC Ratio  $150 million minimum holding company liquidity  25% – 28% debt to total capital ratio Operating Return on Equity  2026 results expected to exceed 2027 target of 12.0%  Expect to establish new long-term operating ROE targets in February 2027, in line with our normal planning cadence

 

13 4 5 3 2 1 Exclusive middle-market focus and “last-mile” captive distribution create a durable competitive moat Significant demographic tailwinds Proven investment results built on a foundation of strong asset quality and disciplined management Strong balance sheet and robust free cash flow resilient against market events WHY INVEST IN CNO 6 Track record of execution and delivering on our promises Sustained growth while improving ROE and modernizing the business

 

14 Questions and Answers

 

15  Cash Flow Profile Slide 16  Broker-Dealer/Registered Investment Advisor Slide 17  Expense Ratio Slide 18  Portfolio Composition Slide 19  New Money Summary Slide 20  Private Credit Slide 21  Financial Results Seasonality Slide 22  Long-Term Care Insurance Slide 23  Tax Asset Summary Slide 24  Glossary of Terms and Definitions Slide 25 Appendix 1: Quarter in Review

 

16 1 Cash flows exclude acquisitions, dividend payments, stock repurchases, and financing transactions. CASH FLOW PROFILE 3Q25 3Q26 3Q25 3Q26 Holding Company Cash Flows: Net Dividends (Contributions) from/to Subsidiaries -$ -$ 69.3$ 293.8$ Management Fees 31.5 34.5 125.1 128.6 Surplus Debenture Interest 29.4 14.8 77.0 59.0 Earnings on Corporate Investments 3.1 3.0 33.7 16.0 Other 32.6 38.8 25.0 45.5 Holding Company Sources of Cash1 96.6 91.1 330.1 542.9 Holding Company Expenses and Other (23.9) (23.7) (83.6) (176.7) Net Tax Receipts (Payments) 13.0 8.2 22.1 57.7 Interest Payments (2.1) (2.1) (110.0) (79.8) Free Cash Flow1 83.6 73.5 158.6 344.1 Notes Payable Repayment - - (500.0) - Share Repurchases (60.6) (59.5) (351.9) (240.5) Dividend Payments to Stockholders (16.4) (16.5) (66.4) (66.6) Net Change in Holding Company Cash and Investments 6.6 (2.5) (759.7) 37.0 Cash and Investments, Beginning of Period 187.1 233.2 953.4 193.7 Cash and Investments, End of Period 193.7$ 230.7$ 193.7$ 230.7$ Trailing Twelve MonthsFor the Quarter (dollars in millions)

 

17 Record client assets in brokerage and advisory; Registered agent count up 4% 1 Client assets include cash and securities in brokerage, broker-dealer customer account assets custodied directly at fund companies and insurance carriers, and assets under management in advisory accounts. Bankers Life is the marketing brand of various affiliated companies of CNO Financial Group including, Bankers Life and Casualty Company, Bankers Life Securities, Inc., and Bankers Life Advisory Services, Inc. Non-affiliated insurance products are offered through Bankers Life General Agency, Inc. (dba BL General Insurance Agency, Inc., AK, AL, CA, NV, PA). Agents who are financial advisors are registered with Bankers Life Securities, Inc. Securities and variable annuity products and services are offered by Bankers Life Securities, Inc. Member FINRA/SIPC, (dba BL Securities, Inc., AL, GA, IA, IL, MI, NV, PA). Advisory products and services are offered by Bankers Life Advisory Services, Inc. SEC Registered Investment Adviser (dba BL Advisory Services, Inc., AL, GA, IA, MT, NV, PA). Home Office: 303 East Wacker Drive, 5th Floor, Chicago, IL 60601. 2 Registered agents are dually licensed as insurance agents and financial representatives who can buy and sell securities for clients, and/or investment advisors who can provide ongoing investment advice for clients. 3 Representative counts represent the average of the last 3 months. BROKER-DEALER/REGISTERED INVESTMENT ADVISOR 3Q 4Q 1Q 2Q 3Q Net New Client Assets in Brokerage 74.1$ 67.6$ 63.1$ 75.1$ 44.1$ Brokerage and Advisory1 Advisory 124.2 (90.2) 99.2 120.6 90.5 Total 198.3$ (22.6)$ 162.3$ 195.7$ 134.6$ Client Assets in Brokerage and Brokerage 2,472.4$ 2,543.2$ 2,521.9$ 2,749.7$ 2,749.0$ Advisory1 at end of period Advisory 2,567.3 2,493.0 2,560.1 2,940.5 3,048.4 Total 5,039.7$ 5,036.2$ 5,082.0$ 5,690.2$ 5,797.4$ Registered Agent Counts 2,3 Total 766 781 794 792 795 20262025 (dollars in millions)

 

18 1 Expense ratio calculation = expenses allocated to products plus not allocated to products, divided by the sum of insurance policy income and net investment income allocated to products. Results exclude significant items. 2 See pages 27-30 for a reconciliation of the significant items. EXPENSE RATIO1 (dollars in millions) 3Q 4Q 1Q 2Q 3Q Allocated & Non Allocated Expenses 173.3$ 169.5$ 179.3$ 176.2$ 179.8$ Allocated & Non Allocated Expenses - YTD 529.5 699.0 179.3 355.5 535.3 Significant Items2 -$ -$ -$ -$ -$ Significant Items - YTD2 - - - - - Allocated & Non Allocated Expenses Excluding Significant Items 173.3$ 169.5$ 179.3$ 176.2$ 179.8$ Allocated & Non Allocated Expenses Excluding Significant Items - YTD 529.5 699.0 179.3 355.5 535.3 Policy Income and Net Investment Income Allocated to Products 929.3$ 935.9$ 946.9$ 958.8$ 970.8$ Policy Income and Net Investment Income Allocated to Products - YTD 2,761.0 3,696.9 946.9 1,905.7 2,876.5 Expense Ratio 18.6% 18.1% 18.9% 18.4% 18.5% Expense Ratio - YTD 19.2% 18.9% 18.9% 18.7% 18.6% Rolling Twelve Months Ratio 19.0% 18.9% 18.7% 18.5% 18.5% 2025 2026

 

19 1 Fair Value as of 9/30/2026. PORTFOLIO COMPOSITION High-quality, liquid portfolio producing solid and consistent results Highlights General Approach $31 Billion of Invested Assets1  High degree of liquidity: over 57% of portfolio in corporate and government bonds  Strong credit risk profile — Capital efficient: ~97% rated NAIC 1 or 2 — Portfolio average rating A — CRE and private credit portfolios performing as expected  Positioned for stable performance across credit cycles  Focus on quality - margin against adverse development  Low impairments through multiple cycles  Embedded asset liability management  Opportunistic investments protect/grow book yield and core earnings power  Growth in AUM leverages increasing book yield, resulting in higher net investment income IG Corporates, 40.5% Non- Agency RMBS, 4.1% Commercial Mortgage Loans, 5.5% Residential Mortgage Loans, 5.1% HY Corporates, 2.1% CMBS, 6.9% Municipals, 8.5% ABS, 6.6% Govts/Agency, 3.2% CLO, 5.2% Equities, 0.9% Other Invested Assets, 2.8% Alternatives, 3.5% Policy Loans, 0.5% Cash, 4.6%

 

20 3Q26 General Account New Money Purchases NEW MONEY SUMMARY (dollars in millions) $ % GAAP YTM IG Corp AAA-A 496.2 29.9% 6.12% ABS 335.4 20.2% 6.00% IG Corp BBB 335.4 20.2% 6.05% Residential Mortgage Loans 153.8 9.3% 6.34% Municipals 97.7 5.9% 5.82% CRE Loans 89.6 5.4% 5.37% Alternatives 58.1 3.5% 11.99% EM 35.9 2.2% 5.63% CMBS 29.0 1.8% 5.54% Rated Notes 20.1 1.2% 6.86% CLO Debt 5.0 0.3% 5.68% HY Corp 2.0 0.1% 7.63% Total 1,658.2 100.0% 0.00%

 

21 PRIVATE CREDIT $2.3B of exposure diversified across asset managers, structures, vintages; 2,000+ underlying credits 1 Non-rated (NR) holdings primarily consist of LPs, residuals, and interval funds, all of which are part of our Alternatives allocation but included here because they have private credit exposure. By Rating1 By Structure ………………………….. By Asset Class By Rating Agency A 33% BBB 29% NR 16% AA 14% BB 4% B 2% AAA 2% ABF Loans 41% Rated Notes 25% Portfolio Finance Loans 17% LP/LLC 6% Residual 6% Interval Fund 5% KBRA 59% Moody 22% DBRS Morningstar 10% Fitch 4% Egan Jones 3% S&P 2%

 

22 FINANCIAL RESULTS SEASONALITY 1Q 2Q 3Q 4Q Medicare Supplement Margin Seasonally highest claims and surrenders Mortality Seasonally highest mortality D2C Advertising Traditionally highest advertising Traditionally lowest advertising Fee Income ~1/3 income Near breakeven Near breakeven ~2/3 income Expenses Traditionally highest expense ratio Traditionally lowest expense ratio Quarterly trend similar to 2025

 

23 New sales focused on short duration products  Recent growth due to strong sales in LTC Fundamental product  99% of new sales for policies with 2 years or less in benefits  Average benefit period of 13 months for policies sold in 2026 Reserve assumptions informed by historical experience  No morbidity improvement  No mortality improvement  Minimal future rate increases Favorable economic profile  Total LTC is just 11% of overall CNO insurance liabilities  Downside risk significantly reduced after 2018 reinsurance transaction  Average maximum benefit at issuance is $168 per day for in-force block Block highlights  Less than 22% of policies have inflation benefits  2% of policies have lifetime benefits, the median benefit period is ~1 year, and the average non-lifetime benefit period is ~1.4 years  Average attained age is 75 years Highly differentiated; prudently-managed in-force block LONG-TERM CARE INSURANCE

 

24 NOLs with no Expiration Date $176 Value of NOLs Details  Remaining NOLs are expected to be fully utilized and can generally offset 80% of non- life taxable income and 35% of life taxable income  Total estimated economic value of tax assets related to our NOLs of approximately $147 million @ 10% discount rate ($1.57 on a per diluted share basis) $176 $176 million / $1.88 per diluted share value of remaining NOLs TAX ASSET SUMMARY AS OF SEPTEMBER 30, 2026 (dollars in millions)

 

25 GLOSSARY OF TERMS AND DEFINITIONS New Annualized Premiums – Measured as 100% of new Life and Health annualized premiums and 10% of Single Premium Whole Life deposits. Fee Revenue – Represents fee revenue from the sales of third-party insurance products, fees generated by our broker-dealer and registered investment advisor, and prior to 4Q25, fee revenue earned by the Worksite Division fee services business. Client Assets in Broker-Dealer (BD) and Advisory – Client assets include cash and securities in brokerage, broker-dealer customer account assets custodied directly at fund companies and insurance carriers, and assets under management in advisory accounts. Producing Agent Counts (PAC) – Producing agents represent the monthly average of exclusive agents that have submitted at least one policy in the month. Sales Growth Measure – Sales growth is measured using 100% of new Life and Health annualized premium, 10% of Single Premium Whole Life deposits, and 6% of Annuity collected premium.

 

26 Appendix 2: Financial Exhibits Non-GAAP Financial Measures Slides 27 - 42

 

27 (dollars in millions, except per-share amounts) The table below summarizes the financial impact of significant items on our 3Q26 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results. 3Q26 SIGNIFICANT ITEMS (a) Comprised of $56.3 million of the net favorable impact arising from our comprehensive annual actuarial review. (b) A non-GAAP measure. See pages 37 and 38 for a reconciliation to the corresponding GAAP measure. Insurance product margin Annuity 87.9$ (20.5)$ (a) 67.4$ Health 149.1 (7.8) (a) 141.3 Life 96.0 (28.0) (a) 68.0 Total insurance product margin 333.0 (56.3) 276.7 Allocated expenses (161.0) - (161.0) Income from insurance products 172.0 (56.3) 115.7 Fee income (1.1) - (1.1) Investment income not allocated to product lines 68.1 - 68.1 Expenses not allocated to product lines (18.8) - (18.8) Operating earnings before taxes 220.2 (56.3) 163.9 Income tax (expense) benefit on operating income (41.1) 11.4 (29.7) Net operating income (b) 179.1$ (44.9)$ 134.2$ Net operating income per diluted share (b) 1.90$ (0.48)$ 1.42$ Three months ended September 30, 2026 Actual results Significant items Excluding significant items

 

28 2025 SIGNIFICANT ITEMS The table below summarizes the financial impact of significant items on our 2025 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results. (dollars in millions, except per-share amounts) Insurance product margin Annuity 238.6$ (16.6)$ (a) 222.0$ Health 556.6 (21.1) (a) 535.5 Life 272.4 (10.4) (a) 262.0 Total insurance product margin 1,067.6 (48.1) 1,019.5 Allocated expenses (611.3) - (611.3) Income from insurance products 456.3 (48.1) 408.2 Fee income 15.2 - 15.2 Investment income not allocated to product lines 169.4 - 169.4 Expenses not allocated to product lines (87.7) - (87.7) Operating earnings before taxes 553.2 (48.1) 505.1 Income tax (expense) benefit on operating income (114.0) 10.6 (103.4) Net operating income (b) 439.2$ (37.5)$ 401.7$ Net operating income per diluted share (b) 4.40$ (0.38)$ 4.02$ Actual Results Significant Items Excluding significant items Year ended December 31, 2025 (a) Comprised of $41.3 million of the net favorable impact arising from our comprehensive annual actuarial review during 3Q25 and $6.8 million of the favorable impact of an out-of-period adjustment which decreased reserves, during 1Q25. (b) A non-GAAP measure. See pages 37 and 38 for a reconciliation to the corresponding GAAP measure.

 

29 (dollars in millions, except per-share amounts) The table below summarizes the financial impact of significant items on our 3Q25 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results. 3Q25 SIGNIFICANT ITEMS (a) Comprised of $41.3 million of the net favorable impact arising from our comprehensive annual actuarial review. (b) A non-GAAP measure. See pages 37 and 38 for a reconciliation to the corresponding GAAP measure. Insurance product margin Annuity 72.9$ (16.6)$ (a) 56.3$ Health 157.0 (21.1) (a) 135.9 Life 70.6 (3.6) (a) 67.0 Total insurance product margin 300.5 (41.3) 259.2 Allocated expenses (151.0) - (151.0) Income from insurance products 149.5 (41.3) 108.2 Fee income (3.9) - (3.9) Investment income not allocated to product lines 39.5 - 39.5 Expenses not allocated to product lines (22.3) - (22.3) Operating earnings before taxes 162.8 (41.3) 121.5 Income tax (expense) benefit on operating income (35.6) 9.1 (26.5) Net operating income (b) 127.2$ (32.2)$ 95.0$ Net operating income per diluted share (b) 1.29$ (0.33)$ 0.96$ Three months ended September 30, 2025 Actual results Significant items Excluding significant items

 

30 (dollars in millions, except per-share amounts) The table below summarizes the financial impact of significant items on our 1Q25 net operating income. Management believes that identifying the impact of these items enhances the understanding of our operating results. 1Q25 SIGNIFICANT ITEMS (a) Comprised of $6.8 million of the favorable impact of an out-of-period adjustment which decreased reserves. (b) A non-GAAP measure. See pages 37 and 38 for a reconciliation to the corresponding GAAP measure. Insurance product margin Annuity 54.5$ -$ 54.5$ Health 126.2 - 126.2 Life 68.2 (6.8) (a) 61.4 Total insurance product margin 248.9 (6.8) 242.1 Allocated expenses (161.2) - (161.2) Income from insurance products 87.7 (6.8) 80.9 Fee income (0.8) - (0.8) Investment income not allocated to product lines 38.0 - 38.0 Expenses not allocated to product lines (20.3) - (20.3) Operating earnings before taxes 104.6 (6.8) 97.8 Income tax (expense) benefit on operating income (23.5) 1.5 (22.0) Net operating income (b) 81.1$ (5.3)$ 75.8$ Net operating income per diluted share (b) 0.79$ (0.05)$ 0.74$ Actual results Significant items Excluding significant items Three months ended March 31, 2025

 

31 3Q25 4Q25 1Q26 2Q26 3Q26 Insurance product margin Annuity 72.9$ 56.4$ 58.5$ 60.6$ 87.9$ Health 157.0 139.4 132.6 147.2 149.1 Life 70.6 70.0 65.8 71.2 96.0 Total insurance product margin 300.5 265.8 256.9 279.0 333.0 Allocated expenses (151.0) (149.7) (159.9) (152.9) (161.0) Income from insurance products 149.5 116.1 97.0 126.1 172.0 Fee income (3.9) 19.1 10.6 (1.2) (1.1) Investment income not allocated to product lines 39.5 58.1 41.7 49.4 68.1 Expenses not allocated to product lines (22.3) (19.8) (19.4) (23.3) (18.8) Operating earnings before taxes 162.8 173.5 129.9 151.0 220.2 Income tax expense on operating income (35.6) (30.1) (28.6) (31.5) (41.1) Net operating income* 127.2 143.4 101.3 119.5 179.1 Net realized investment gains (losses) from disposals, impairments and change in allowance for credit losses (8.8) (25.2) (15.2) (13.6) (48.3) Net change in market value of investments recognized in earnings 5.8 (1.3) (7.5) (1.1) (16.4) Fair value changes related to agent deferred compensation plan - (1.7) - - 10.0 Changes in fair value of embedded derivative liabilities and market risk benefits (18.1) (1.5) (42.4) 34.6 69.7 Expenses related to TechMod initiative (7.2) (9.9) (13.7) (9.7) (10.1) Goodwill and other asset impairment (96.7) (5.2) - - - Net loss related to divested business - (17.3) (1.9) (1.1) - Other (1.6) - (0.8) (0.4) 1.3 Non-operating income (loss) before taxes (126.6) (62.1) (81.5) 8.7 6.2 Income tax (expense) benefit on non-operating income (loss) 22.5 11.6 17.9 (2.3) (2.1) Valuation allowance for deferred tax assets - - - - (22.1) Net non-operating income (loss) (104.1) (50.5) (63.6) 6.4 (18.0) Net income 23.1$ 92.9$ 37.7$ 125.9$ 161.1$ *Management believes that an analysis of net income applicable to common stock before the following items (each net of tax, except as noted) is important to evaluate the financial performance of the Company, and is a key measure commonly used in the life insurance industry: (i) net realized investment gains or losses from disposals, impairments and the change in allowance for credit losses; (ii) net change in market value of investments recognized in earnings; (iii) changes in fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities; (iv) fair value changes related to the agent deferred compensation plan; (v) gains or losses related to material reinsurance transactions; (vi) loss on extinguishment of debt; (vii) changes in the valuation allowance for deferred tax assets and other tax items; (viii) costs related to our three-year project to modernize certain elements of our technology ("TechMod") that are incremental to normal spend and will not recur following implementation; (ix) goodwill and other asset impairment expenses; (x) gains or losses related to divested business; and (xi) other non-operating items including earnings attributable to variable interest entities (collectively, "net operating income," a non-GAAP financial measure). The income tax expense or benefit allocated to the items included in net non-operating income (loss) represents the current and deferred income tax expense or benefit allocated to the items included in non-operating earnings. Management believes this information provides a better understanding of the business and a more meaningful analysis of results of our insurance product lines. A reconciliation of net operating income to net income applicable to common stock is provided in the table on page 33. QUARTERLY EARNINGS (dollars in millions)

 

32 The following provides additional information regarding certain non-GAAP measures used in this presentation. A non-GAAP measure is a numerical measure of a company’s performance, financial position, or cash flows that excludes or includes amounts that are normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. While management believes these measures are useful to enhance understanding and comparability of our financial results, these non-GAAP measures should not be considered as substitutes for the most directly comparable GAAP measures. Additional information concerning non-GAAP measures is included in our periodic filings with the Securities and Exchange Commission that are available in the “Investors – SEC Filings” section of CNO’s website, www.CNOinc.com. Operating earnings measures Management believes that an analysis of net income applicable to common stock before the following items (each net of tax, except as noted) is important to evaluate the financial performance of the Company, and is a key measure commonly used in the life insurance industry: (i) net realized investment gains or losses from disposals, impairments and the change in allowance for credit losses; (ii) net change in market value of investments recognized in earnings; (iii) changes in fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities; (iv) fair value changes related to the agent deferred compensation plan; (v) gains or losses related to material reinsurance transactions; (vi) loss on extinguishment of debt; (vii) changes in the valuation allowance for deferred tax assets and other tax items; (viii) costs related to our three-year project to modernize certain elements of our technology ("TechMod") that are incremental to normal spend and will not recur following implementation; (ix) goodwill and other asset impairment expenses; (x) gains or losses related to divested business; and (xi) other non-operating items including earnings attributable to variable interest entities (collectively, "net operating income," a non-GAAP financial measure). The income tax expense or benefit allocated to the items included in net non-operating income (loss) represents the current and deferred income tax expense or benefit allocated to the items included in non-operating earnings. Management believes this information provides a better understanding of the business and a more meaningful analysis of results of our insurance product lines. A reconciliation of net operating income to net income applicable to common stock is provided in the table on page 33. INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES

 

33 (dollars in millions, except per-share amounts) INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES 3Q25 4Q25 1Q26 2Q26 3Q26 Net income applicable to common stock 23.1$ 92.9$ 37.7$ 125.9$ 161.1$ Non-operating items: Net realized investment (gains) losses from sales and impairments 8.8 25.2 15.2 13.6 48.3 Net change in market value of investments recognized in earnings (5.8) 1.3 7.5 1.1 16.4 Fair value changes related to the agent deferred compensation plan - 1.7 - - (10.0) Changes in fair value of embedded derivative liabilities and market risk benefits 18.1 1.5 42.4 (34.6) (69.7) Expenses related to TechMod initiative 7.2 9.9 13.7 9.7 10.1 Goodwill and other asset impairment 96.7 5.2 - - - Net loss related to divested business - 17.3 1.9 1.1 - Other 1.6 - 0.8 0.4 (1.3) Non-operating (income) loss before taxes 126.6 62.1 81.5 (8.7) (6.2) Income tax expense (benefit) on non-operating income (22.5) (11.6) (17.9) 2.3 2.1 Valuation allowance for deferred tax assets - - - - 22.1 Net non-operating (income) loss 104.1 50.5 63.6 (6.4) 18.0 Net operating income (a non-GAAP financial measure) 127.2$ 143.4$ 101.3$ 119.5$ 179.1$ Per diluted share: Net income 0.24$ 0.95$ 0.39$ 1.33$ 1.71$ Net realized investment (gains) losses from sales and impairments (net of taxes) 0.07 0.22 0.12 0.11 0.41 Net change in market value of investments recognized in earnings (net of taxes) (0.05) 0.01 0.06 0.01 0.14 Changes in fair value of embedded derivative liabilities and market risk benefits (net of taxes) 0.14 0.02 0.34 (0.28) (0.59) Fair value changes related to the agent deferred compensation plan (net of taxes) - 0.01 - - (0.08) Expenses related to TechMod initiative 0.06 0.08 0.11 0.08 0.09 Goodwill and other asset impairment 0.82 0.04 - - - Net loss related to divested business - 0.14 0.02 0.01 - Valuation allowance for deferred tax assets - - - - 0.23 Other 0.01 - 0.01 - (0.01) Net operating income (a non-GAAP financial measure) 1.29$ 1.47$ 1.05$ 1.26$ 1.90$ A reconciliation of net income applicable to common stock to net operating income (and related per-share amounts) is as follows:

 

34 A reconciliation of operating income and shares used to calculate basic and diluted operating earnings per share is as follows: (dollars in millions, except per-share amounts, and shares in thousands) INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES 3Q25 4Q25 1Q26 2Q26 3Q26 Net operating income 127.2$ 143.4$ 101.3$ 119.5$ 179.1$ Weighted average shares outstanding for basic earnings per share 96,603 95,136 94,078 93,194 92,195 Effect of dilutive securities on weighted average shares: Employee benefit plans 1,951 2,142 2,061 1,758 2,059 Weighted average shares outstanding for diluted earnings per share 98,553 97,278 96,139 94,952 94,253 Net operating income per diluted share 1.29$ 1.47$ 1.05$ 1.26$ 1.90$

 

35 Book value per diluted share Book value per diluted share reflects the potential dilution that could occur if outstanding stock options were exercised and restricted stock and performance units were vested. The dilution from options, restricted shares and performance units is calculated using the treasury stock method. Under this method, we assume the proceeds from the exercise of the options (or the unrecognized compensation expense with respect to restricted stock and performance units) will be used to purchase shares of our common stock at the closing market price on the last day of the period. In addition, the calculation of this non-GAAP measure differs from the corresponding GAAP measure because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure. Management believes this non- GAAP measure is useful because it removes the volatility that arises from changes in the unrealized appreciation (depreciation) of our investments. A reconciliation from book value per share to book value per diluted share, excluding accumulated other comprehensive income (loss) is as follows: INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES 3Q25 4Q25 1Q26 2Q26 3Q26 Total shareholders' equity 2,611.0$ 2,638.2$ 2,498.4$ 2,591.6$ 2,323.7$ Shares outstanding for the period 95,840,989 94,484,339 93,795,306 92,696,990 91,705,509 Book value per share 27.24$ 27.92$ 26.64$ 27.96$ 25.34$ Total shareholders' equity 2,611.0$ 2,638.2$ 2,498.4$ 2,591.6$ 2,323.7$ Accumulated other comprehensive loss (1,118.9) (1,115.0) (1,217.6) (1,182.8) (1,545.8) Adjusted shareholders' equity excluding AOCI 3,729.9$ 3,753.2$ 3,716.0$ 3,774.4$ 3,869.5$ Shares outstanding for the period 95,840,989 94,484,339 93,795,306 92,696,990 91,705,509 Dilutive common stock equivalents related to: Stock options, restricted stock and performance units 2,061,774 2,229,874 1,528,160 1,854,426 2,015,117 Diluted shares outstanding 97,902,763 96,714,213 95,323,466 94,551,416 93,720,626 Book value per diluted share excluding AOCI (a non-GAAP measure) $ 38.10 $ 38.81 $ 38.98 $ 39.92 $ 41.29 (dollars in millions, except share and per-share amounts)

 

36 Operating return measures Management believes that an analysis of net income applicable to common stock before the following items (each net of tax, except as noted) is important to evaluate the financial performance of the Company, and is a key measure commonly used in the life insurance industry: (i) net realized investment gains or losses from disposals, impairments and the change in allowance for credit losses; (ii) net change in market value of investments recognized in earnings; (iii) changes in fair value of embedded derivative liabilities and market risk benefits related to our fixed indexed annuities; (iv) fair value changes related to the agent deferred compensation plan; (v) gains or losses related to material reinsurance transactions; (vi) loss on extinguishment of debt; (vii) changes in the valuation allowance for deferred tax assets and other tax items; (viii)costs related to our three-year project to modernize certain elements of our technology ("TechMod") that are incremental to normal spend and will not recur following implementation; (ix) goodwill and other asset impairment expenses; (x) gains or losses related to divested business; and (xi) other non-operating items including earnings attributable to variable interest entities (collectively, "net operating income," a non-GAAP financial measure). The income tax expense or benefit allocated to the items included in net non-operating income (loss) represents the current and deferred income tax expense or benefit allocated to the items included in non-operating earnings. Management believes this information provides a better understanding of the business and a more meaningful analysis of results of our insurance product lines. Management also believes that an operating return, excluding significant items, is important as the impact of these items enhances the understanding of our operating results. This non-GAAP financial measure also differs from return on equity because accumulated other comprehensive income (loss) has been excluded from the value of equity used to determine this ratio. Management believes this non-GAAP financial measure is useful because it removes the volatility that arises from changes in accumulated other comprehensive income (loss). Such volatility is often caused by changes in the estimated fair value of our investment portfolio resulting from changes in general market interest rates rather than the business decisions made by management. In addition, our equity includes the value of significant net operating loss carryforwards (included in income tax assets on our consolidated balance sheet). In accordance with GAAP, these assets are not discounted and accordingly will not provide a return to shareholders (until after it is realized as a reduction to taxes that would otherwise be paid). Management believes that excluding this value from the equity component of this measure enhances the understanding of the effect these non-discounted assets have on operating returns and the comparability of these measures from period-to-period. Operating return measures are used in measuring the performance of our business units and are used as a basis for incentive compensation. INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES

 

37 The calculations of: (i) Operating return on equity (a non-GAAP financial measure); (ii) Operating return, excluding significant items, on equity (a non-GAAP financial measure); and (iii) return on equity are as follows: (dollars in millions) (Continued on next page) Trailing four quarters average equity is calculated using the following formula (P = Period) – ((P1+P2) /2 +(P2+P3) /2 +(P3+P4) /2 + (P4+P5) /2) /4 [e.g. – the formula for calculating 3Q26 average equity would be the following – ((3Q25+4Q25) /2) + (4Q25+1Q26) /2) + (1Q26+2Q26) /2) + (2Q26+3Q26) /2) /4 ] INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES 3Q25 4Q25 1Q26 2Q26 3Q26 Net operating income 433.8$ 439.2$ 459.4$ 491.4$ 543.3$ Net operating income, excluding significant items 399.4$ 401.7$ 427.2$ 459.2$ 498.4$ Net income 319.3$ 229.3$ 245.5$ 279.6$ 417.6$ Average common equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) 3,580.0$ 3,536.7$ 3,494.5$ 3,495.4$ 3,522.7$ Average common shareholders' equity 2,560.6$ 2,566.4$ 2,574.7$ 2,576.2$ 2,548.9$ Operating return on equity (a non-GAAP financial measure) 12.1% 12.4% 13.1% 14.1% 15.4% Operating return on equity, excluding significant items (a non-GAAP financial measure) 11.2% 11.4% 12.2% 13.1% 14.1% Return on equity 12.5% 8.9% 9.5% 10.9% 16.4% Twelve Months Ended

 

38 The following summarizes: (i) operating earnings; (ii) significant items; (iii) operating earnings, excluding significant items; and (iv) net income (loss): (dollars in millions) (a) The significant items have been discussed in either the current or prior press releases. (Continued on next page) INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES Net operating income Significant items (a) Net operating income, excluding significant items Net operating income, excluding significant items - trailing four quarters Net income (loss) Net income - trailing four quarters 4Q24 138.0$ 3.1$ 141.1$ 410.5$ 182.9$ 420.8$ 1Q25 81.1 (5.3) 75.8 428.8 21.5 330.0 2Q25 87.5 - 87.5 401.7 91.8 305.5 3Q25 127.2 (32.2) 95.0 399.4 23.1 319.3 4Q25 143.4 - 143.4 401.7 92.9 229.3 1Q26 101.3 - 101.3 427.2 37.7 245.5 2Q26 119.5 - 119.5 459.2 125.9 279.6 3Q26 179.1 (44.9) 134.2 498.4 161.1 417.6

 

39 The calculations of: (i) operating return on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure); (ii) operating return, excluding significant item, on equity, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure); and (iii) return on equity are as follows: (dollars in millions) (Continued on next page) INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES 3Q25 4Q25 1Q26 2Q26 3Q26 Pre-tax operating earnings (a non-GAAP financial measure) 553.6$ 553.2$ 578.5$ 617.2$ 674.6$ Income tax expense (119.8) (114.0) (119.1) (125.8) (131.3) Operating return 433.8 439.2 459.4 491.4 543.3 Non-operating items: Net realized investment losses from sales and impairments (78.9) (69.0) (71.0) (62.8) (102.3) Net change in market value of investments recognized in earnings 9.0 14.3 0.4 (4.1) (26.3) Changes in fair value of embedded derivative liabilities and market risk benefits 30.1 (64.0) (36.8) (27.4) 60.4 Fair value changes and amendment related to the agent deferred compensation plan 6.6 (1.7) (1.7) (1.7) 8.3 Expenses related to TechMod initiative (10.4) (20.3) (34.0) (40.5) (43.4) Goodwill and other asset impairment (96.7) (101.9) (101.9) (101.9) (5.2) Net loss related to divested business - (17.3) (19.2) (20.3) (20.3) Other 0.8 0.1 (0.3) (2.8) 0.1 Non-operating income (loss) before taxes (139.5) (259.8) (264.5) (261.5) (128.7) Income tax (expense) benefit on non-operating income (loss) 25.0 49.9 50.6 49.7 25.1 Valuation allowance for deferred tax assets - - - - (22.1) Net non-operating income (loss) (114.5) (209.9) (213.9) (211.8) (125.7) Net income 319.3$ 229.3$ 245.5$ 279.6$ 417.6$ Twelve Months Ended

 

40 A reconciliation of consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) to common shareholders’ equity, is as follows: (dollars in millions) 1Q24 2Q24 3Q24 4Q24 Consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) 3,536.8$ 3,596.7$ 3,529.9$ 3,810.0$ Net operating loss carryforwards 311.2 296.5 273.9 76.6 Accumulated other comprehensive loss (1,480.3) (1,464.3) (1,116.0) (1,371.4) Common shareholders' equity 2,367.7$ 2,428.9$ 2,687.8$ 2,515.2$ 1Q25 2Q25 3Q25 4Q25 Consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) 3,498.9$ 3,504.3$ 3,483.6$ 3,510.2$ Net operating loss carryforwards 295.3 271.1 246.3 243.0 Accumulated other comprehensive loss (1,239.1) (1,252.7) (1,118.9) (1,115.0) Common shareholders' equity 2,555.1$ 2,522.7$ 2,611.0$ 2,638.2$ 1Q26 2Q26 3Q26 Consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) 3,461.2$ 3,548.5$ 3,658.3$ Net operating loss carryforwards 254.8 225.9 211.2 Accumulated other comprehensive loss (1,217.6) (1,182.8) (1,545.8) Common shareholders' equity 2,498.4$ 2,591.6$ 2,323.7$ INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES

 

41 A reconciliation of consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) to common shareholders’ equity, is as follows: (dollars in millions) INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES 3Q25 4Q25 1Q26 2Q26 3Q26 Consolidated capital, excluding accumulated other comprehensive income (loss) and net operating loss carryforwards (a non-GAAP financial measure) 3,580.0$ 3,536.7$ 3,494.5$ 3,495.4$ 3,522.7$ Net operating loss carryforwards 225.8 243.1 258.9 248.1 238.1 Accumulated other comprehensive loss (1,245.2) (1,213.4) (1,178.7) (1,167.3) (1,211.9) Common shareholders' equity 2,560.6$ 2,566.4$ 2,574.7$ 2,576.2$ 2,548.9$ Trailing Four Quarter Average

 

42 2024 2025 1Q26 2Q26 3Q26 Corporate notes payable 1,833.5$ 1,335.6$ 1,336.0$ 1,336.3$ 1,336.7$ Total shareholders' equity 2,515.2 2,638.2 2,498.4 2,591.6 2,323.7 Total capital 4,348.7$ 3,973.8$ 3,834.4$ 3,927.9$ 3,660.4$ Corporate debt to capital 42.2% 33.6% 34.8% 34.0% 36.5% Corporate notes payable 1,833.5$ 1,335.6$ 1,336.0$ 1,336.3$ 1,336.7$ Total shareholders' equity 2,515.2 2,638.2 2,498.4 2,591.6 2,323.7 Less accumulated other comprehensive (income) loss 1,371.4 1,115.0 1,217.6 1,182.8 1,545.8 Total capital 5,720.1$ 5,088.8$ 5,052.0$ 5,110.7$ 5,206.2$ Debt to total capital ratio, excluding AOCI (a non-GAAP financial measure) 32.1% 26.2% 26.4% 26.1% 25.7% Corporate notes payable $1,833.5 Assumed repayment of 2025 notes, net of unamortized debt issuance costs (499.5) Adjusted corporate notes payable $1,334.0 Total shareholders' equity $2,515.2 Less accumulated other comprehensive loss 1,371.4 Loss on assumed extinguishment of debt (0.4) Adjusted shareholders' equity $3,886.2 Adjusted total capital $5,220.2 Debt to total capital ratio, excluding AOCI, as adjusted for the assumed repayment of the 2025 Notes (a non- GAAP financial measure) 25.6% Debt to capital ratio, excluding accumulated other comprehensive income (loss) The debt to capital ratio, excluding accumulated other comprehensive income (loss), differs from the debt to capital ratio because accumulated other comprehensive income (loss) has been excluded from the value of capital used to determine this measure. Management believes this non-GAAP financial measure is useful because it removes the volatility that arises from changes in accumulated other comprehensive income (loss). Such volatility is often caused by changes in the estimated fair value of our investment portfolio resulting from changes in general market interest rates rather than the business decisions made by management. A reconciliation of these ratios is as follows: (dollars in millions) INFORMATION RELATED TO CERTAIN NON-GAAP FINANCIAL MEASURES

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

7 documents

Press Releases

Other Documents

Keep reading

More on CNO

All CNO news

Trending in the feed

SNDK
Sandisk Reports Fiscal First Quarter 2027 Financial Results Open the live feed